Aripiprazole (Abilify) vs Brexpiprazole (Rexulti)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline

Aripiprazole (Abilify)

Marketed by Otsuka Holdings and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00712686 · Phase 3 · completed

A randomised, double-blind, active-controlled trial of aripiprazole (n=355) against olanzapine (n=348) in acute schizophrenia, with two co-primary objectives. The published results are mixed: olanzapine was statistically superior on PANSS efficacy at week 6, so aripiprazole did not show non-inferiority, while aripiprazole caused significantly less weight gain at week 26. The registry has no posted results; the figures are from the publication (Fleischhacker et al., Biol Psychiatry 2009).

Next expected readout: July 2030 · NCT06969755 (registry estimate)

Reported efficacy

The mean change in the PANSS Total Score (from baseline to Week 6); The percentage of patients showing significant weight gain (a≥ 7% increase) (from baseline to Week 26): Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05). (mixed)

Result source: NCT00712686

Brexpiprazole (Rexulti)

Marketed by Otsuka Holdings and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT01393613 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 674 patients with acute schizophrenia, using a validated symptom-severity scale (PANSS) as the primary measure. The pooled comparison of the two higher doses against placebo reached statistical significance (p=0.0093), and the 4 mg dose was significant on its own (p=0.0022), but the 1 mg and 2 mg doses individually did not separate from placebo, so the result was only partially met.

Next expected readout: August 2027 · NCT07742280 (registry estimate)

Reported efficacy

Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014 (met)

Result source: NCT03198078

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAripiprazole (Abilify)Brexpiprazole (Rexulti)
PANSS total, change-26.7 vs -21.2−5.5 vs placebo10 mg/day · wk 6 · n 99NCT00102063
31 other results
  • -28.6 vs -21.2 30 mg/day · wk 6 · n 97 · Phase 3 · primary NCT00102063
  • -19.4 vs -22.9 wk 6 · n 33 · Phase 3 · primary NCT02054702
  • -1.3 vs 4.8 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 4.7 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.7 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.8 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.9 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 4.9 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.1 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.2 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 5.4 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 5.8 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 6.2 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 5.6 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.7 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.8 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 5.9 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • -0.3 vs 6.1 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 6.1 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • -0.7 vs 5.6 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.6 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 5.5 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 4.5 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 3.9 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • -1.6 vs 3.7 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 2.9 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 1.6 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 1.8 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs -0.6 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.2 vs -0.3 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -7.7 vs -9.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
-16.6 vs -13.5−3.1 vs placebo2 mg · wk 6 · n 179NCT01393613
71 other results
  • -20.7 vs -12.0 2 mg · wk 6 · n 132 · Phase 3 · primary NCT01396421
  • -14.9 vs -7.6 2 mg · wk 6 · n 113 · Phase 2/3 · primary NCT01451164
  • -14.1 vs -11.9 2 mg · wk 5 · n 179 · Phase 3 · primary NCT01393613
  • -14.0 vs -6.6 2 mg · wk 5 · n 113 · Phase 2/3 · primary NCT01451164
  • -13.1 vs -11.1 2 mg · wk 4 · n 179 · Phase 3 · primary NCT01393613
  • -12.3 vs -5.7 2 mg · wk 4 · n 113 · Phase 2/3 · primary NCT01451164
  • -10.7 vs -8.9 2 mg · wk 3 · n 179 · Phase 3 · primary NCT01393613
  • -11 vs -6 2 mg · wk 3 · n 113 · Phase 2/3 · primary NCT01451164
  • -8.7 vs -6.6 2 mg · wk 2 · n 179 · Phase 3 · primary NCT01393613
  • -7.9 vs -4.5 2 mg · wk 2 · n 113 · Phase 2/3 · primary NCT01451164
  • -4.3 vs -3.5 2 mg · wk 1 · n 179 · Phase 3 · primary NCT01393613
  • -4.6 vs -3.1 2 mg · wk 1 · n 113 · Phase 2/3 · primary NCT01451164
  • -20 vs -13.5 4 mg · wk 6 · n 181 · Phase 3 · primary NCT01393613
  • -19.6 vs -12.0 4 mg · wk 6 · n 134 · Phase 3 · primary NCT01396421
  • -11.5 vs -7.6 4 mg · wk 6 · n 109 · Phase 2/3 · primary NCT01451164
  • -17.3 vs -11.9 4 mg · wk 5 · n 181 · Phase 3 · primary NCT01393613
  • -11.1 vs -6.6 4 mg · wk 5 · n 109 · Phase 2/3 · primary NCT01451164
  • -15.6 vs -11.1 4 mg · wk 4 · n 181 · Phase 3 · primary NCT01393613
  • -11.2 vs -5.7 4 mg · wk 4 · n 109 · Phase 2/3 · primary NCT01451164
  • -12.6 vs -8.9 4 mg · wk 3 · n 181 · Phase 3 · primary NCT01393613
  • -9.4 vs -6 4 mg · wk 3 · n 109 · Phase 2/3 · primary NCT01451164
  • -8.4 vs -6.6 4 mg · wk 2 · n 181 · Phase 3 · primary NCT01393613
  • -6.8 vs -4.5 4 mg · wk 2 · n 109 · Phase 2/3 · primary NCT01451164
  • -5.6 vs -3.5 4 mg · wk 1 · n 181 · Phase 3 · primary NCT01393613
  • -3.4 vs -3.1 4 mg · wk 1 · n 109 · Phase 2/3 · primary NCT01451164
  • -16.9 vs -13.5 1 mg · wk 6 · n 117 · Phase 3 · primary NCT01393613
  • -8.3 vs -7.6 1 mg · wk 6 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.5 vs -11.9 1 mg · wk 5 · n 117 · Phase 3 · primary NCT01393613
  • -8.1 vs -6.6 1 mg · wk 5 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.0 vs -11.1 1 mg · wk 4 · n 117 · Phase 3 · primary NCT01393613
  • -8.4 vs -5.7 1 mg · wk 4 · n 112 · Phase 2/3 · primary NCT01451164
  • -11.6 vs -8.9 1 mg · wk 3 · n 117 · Phase 3 · primary NCT01393613
  • -6.9 vs -6 1 mg · wk 3 · n 112 · Phase 2/3 · primary NCT01451164
  • -7.6 vs -6.6 1 mg · wk 2 · n 117 · Phase 3 · primary NCT01393613
  • -5.1 vs -4.5 1 mg · wk 2 · n 112 · Phase 2/3 · primary NCT01451164
  • -3.3 vs -3.5 1 mg · wk 1 · n 117 · Phase 3 · primary NCT01393613
  • -2.7 vs -3.1 1 mg · wk 1 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.9 vs -12.0 0.25 mg · wk 6 · n 62 · Phase 3 · primary NCT01396421
  • -22.8 vs -17.4 wk 6 · n 110 · Phase 3 · primary NCT03198078
  • -20 vs -15.9 wk 6 · n 150 · Phase 3 · primary NCT01810380
  • -22.9 vs -19.4 wk 6 · n 64 · Phase 3 · primary NCT02054702
  • -17.9 vs -10.8 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01396421
  • -14.1 vs -8.9 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01396421
  • -11.1 vs -7.6 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01396421
  • -8.9 vs -5.1 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01396421
  • -4.9 vs -2.9 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01396421
  • -18.6 vs -10.8 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -16.5 vs -8.9 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -12.8 vs -7.6 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -9.5 vs -5.1 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -4.4 vs -2.9 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -11.9 vs -10.8 0.25 mg · wk 5 · n 87 · Phase 3 · secondary NCT01396421
  • -8.9 vs -8.9 0.25 mg · wk 4 · n 87 · Phase 3 · secondary NCT01396421
  • -5.7 vs -7.6 0.25 mg · wk 3 · n 87 · Phase 3 · secondary NCT01396421
  • -3.3 vs -5.1 0.25 mg · wk 2 · n 87 · Phase 3 · secondary NCT01396421
  • -2.5 vs -2.9 0.25 mg · wk 1 · n 87 · Phase 3 · secondary NCT01396421
  • 0.6 vs 6.9 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 3.3 vs 11.2 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -2.7 vs 3.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 2.5 vs 10.5 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -1.9 vs 2.9 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 9.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 6.2 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 6.6 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 4.1 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • 0.5 vs 3.6 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -9.8 vs -14.4 0.25 mg · wk 6 · n 41 · Phase 2 · primary NCT00905307
  • -18.7 vs -14.4 Low-dose · wk 6 · n 88 · Phase 2 · primary NCT00905307
  • -16.2 vs -14.4 Mid-dose · wk 6 · n 90 · Phase 2 · primary NCT00905307
  • -18.3 vs -14.4 High-dose · wk 6 · n 92 · Phase 2 · primary NCT00905307
  • -3.7 vs -0.3 wk 12 · n 21 · Phase 4 · secondary NCT03526354
CGI-S, change-1.2 vs -0.9−0.3 vs placebo10 mg/day · wk 6 · n 99NCT00102063
32 other results
  • -1.3 vs -0.9 30 mg/day · wk 6 · n 97 · Phase 3 · secondary NCT00102063
  • 0.1 vs 0.3 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.2 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0 vs 0.0 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.0 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
  • -1.3 vs -1.6 wk 6 · n 33 · Phase 3 · secondary NCT02054702
  • -0.1 vs -0.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
-1.0 vs -0.8−0.2 vs placebo2 mg · wk 6 · n 180NCT01393613
71 other results
  • -1.1 vs -0.8 2 mg · wk 6 · n 124 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.6 2 mg · wk 6 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.7 2 mg · wk 5 · n 181 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.5 2 mg · wk 5 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 2 mg · wk 4 · n 181 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.4 2 mg · wk 4 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01393613
  • -0.6 vs -0.5 2 mg · wk 3 · n 181 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 2 mg · wk 3 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.3 2 mg · wk 2 · n 181 · Phase 3 · secondary NCT01396421
  • -0.4 vs -0.3 2 mg · wk 2 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 2 mg · wk 1 · n 181 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.1 2 mg · wk 1 · n 113 · Phase 2/3 · secondary NCT01451164
  • -1.2 vs -0.8 4 mg · wk 6 · n 183 · Phase 3 · secondary NCT01393613
  • -1.2 vs -0.8 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.6 4 mg · wk 6 · n 109 · Phase 2/3 · secondary NCT01451164
  • -1.0 vs -0.7 4 mg · wk 5 · n 183 · Phase 3 · secondary NCT01393613
  • -1.1 vs -0.7 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 4 mg · wk 5 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.6 4 mg · wk 4 · n 183 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.5 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 4 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.4 4 mg · wk 3 · n 183 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 3 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 4 mg · wk 2 · n 183 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.3 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.3 4 mg · wk 2 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 4 mg · wk 1 · n 183 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 4 mg · wk 1 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.9 vs -0.8 1 mg · wk 6 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.6 1 mg · wk 6 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 1 mg · wk 5 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.5 1 mg · wk 5 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 1 mg · wk 4 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.4 1 mg · wk 4 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 1 mg · wk 3 · n 120 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.4 1 mg · wk 3 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.3 vs -0.4 1 mg · wk 2 · n 120 · Phase 3 · secondary NCT01393613
  • -0.3 vs -0.3 1 mg · wk 2 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.1 vs -0.1 1 mg · wk 1 · n 120 · Phase 3 · secondary NCT01393613
  • -0.1 vs -0.1 1 mg · wk 1 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.8 0.25 mg · wk 6 · n 56 · Phase 3 · secondary NCT01396421
  • -0.7 vs -0.7 0.25 mg · wk 5 · n 89 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 0.25 mg · wk 4 · n 89 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.5 0.25 mg · wk 3 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.3 0.25 mg · wk 2 · n 89 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 0.25 mg · wk 1 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs 0.3 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 0.0 vs 0.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -0.3 vs 0.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 0 vs 0.6 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -0.2 vs 0.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.5 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.4 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.3 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.9 vs -0.8 wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • -0.0 vs 0.3 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -0.1 vs 0.2 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -1.2 vs -0.9 wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • -1.6 vs -1.3 wk 6 · n 64 · Phase 3 · secondary NCT02054702
  • -0.4 vs -0.8 0.25 mg · wk 6 · n 41 · Phase 2 · secondary NCT00905307
  • -1.0 vs -0.8 Low-dose · wk 6 · n 88 · Phase 2 · secondary NCT00905307
  • -0.9 vs -0.8 Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • -1.1 vs -0.8 High-dose · wk 6 · n 92 · Phase 2 · secondary NCT00905307
  • -0.3 vs -0.1 wk 12 · n 21 · Phase 4 · secondary NCT03526354
PANSS response—Not posted · NCT0348541738.5% vs 31.7%+6.8 vs placebo2 mg · wk 6 · n 179NCT01393613
8 other results
  • 49.7% vs 31.7% 4 mg · wk 6 · n 181 · Phase 3 · secondary NCT01393613
  • 43.6% vs 31.7% 1 mg · wk 6 · n 117 · Phase 3 · secondary NCT01393613
  • 43.6% vs 28.2% wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • 48.7% vs 32.1% wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • 40.5% vs 49.5% 0.25 mg · wk 6 · n 42 · Phase 2 · secondary NCT00905307
  • 57.3% vs 49.5% Low-dose · wk 6 · n 89 · Phase 2 · secondary NCT00905307
  • 46.7% vs 49.5% Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • 51.6% vs 49.5% High-dose · wk 6 · n 93 · Phase 2 · secondary NCT00905307
PSP, change—Not posted · NCT0348541710.5 vs 8.5+2 vs placebo2 mg · wk 6 · n 170NCT01393613
17 other results
  • 13.2 vs 10.3 2 mg · wk 6 · n 122 · Phase 3 · secondary NCT01396421
  • 6.8 vs 5.8 2 mg · wk 3 · n 170 · Phase 3 · secondary NCT01393613
  • 13.1 vs 8.5 4 mg · wk 6 · n 174 · Phase 3 · secondary NCT01393613
  • 12.7 vs 10.3 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • 7.1 vs 5.8 4 mg · wk 3 · n 174 · Phase 3 · secondary NCT01393613
  • 11.7 vs 8.5 1 mg · wk 6 · n 105 · Phase 3 · secondary NCT01393613
  • 7.0 vs 5.8 1 mg · wk 3 · n 105 · Phase 3 · secondary NCT01393613
  • 11.8 vs 10.3 0.25 mg · wk 6 · n 55 · Phase 3 · secondary NCT01396421
  • 18.6 vs 12.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 15.1 vs 10.3 wk 52 · n 94 · Phase 3 · secondary NCT01668797
  • 18.9 vs 17.8 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 15.2 vs 11.4 wk 24 · n 94 · Phase 3 · secondary NCT01668797
  • 13 vs 9.4 wk 6 · n 133 · Phase 3 · secondary NCT01810380
  • 4.5 vs 7.6 0.25 mg · wk 6 · n 39 · Phase 2 · secondary NCT00905307
  • 11.4 vs 7.6 Low-dose · wk 6 · n 86 · Phase 2 · secondary NCT00905307
  • 10.7 vs 7.6 Mid-dose · wk 6 · n 84 · Phase 2 · secondary NCT00905307
  • 12.2 vs 7.6 High-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
Relapse (% of patients)19.4% vs 37.5%−18.1 vs placebowk 52 · n 98NCT01149655
1 other result
  • 10% vs 39.6% wk 52 · n 269 · Phase 3 · secondary NCT00705783
13.5% vs 38.5%−24.9 vs placebowk 52 · n 96NCT01668797

PANSS total, change

Aripiprazole (Abilify)
-26.7 vs -21.2−5.5 vs placebo10 mg/day · wk 6 · n 99NCT00102063
31 other results
  • -28.6 vs -21.2 30 mg/day · wk 6 · n 97 · Phase 3 · primary NCT00102063
  • -19.4 vs -22.9 wk 6 · n 33 · Phase 3 · primary NCT02054702
  • -1.3 vs 4.8 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 4.7 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.7 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.8 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 4.9 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 4.9 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.1 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.2 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 5.4 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • -1.1 vs 5.8 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 6.2 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • -1.0 vs 5.6 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.7 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • -0.9 vs 5.8 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 5.9 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • -0.3 vs 6.1 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 6.1 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • -0.7 vs 5.6 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs 5.6 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 5.5 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • -0.2 vs 4.5 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 3.9 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • -1.6 vs 3.7 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • -1.2 vs 2.9 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • -0.6 vs 1.6 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • -0.4 vs 1.8 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs -0.6 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.2 vs -0.3 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -7.7 vs -9.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
Brexpiprazole (Rexulti)
-16.6 vs -13.5−3.1 vs placebo2 mg · wk 6 · n 179NCT01393613
71 other results
  • -20.7 vs -12.0 2 mg · wk 6 · n 132 · Phase 3 · primary NCT01396421
  • -14.9 vs -7.6 2 mg · wk 6 · n 113 · Phase 2/3 · primary NCT01451164
  • -14.1 vs -11.9 2 mg · wk 5 · n 179 · Phase 3 · primary NCT01393613
  • -14.0 vs -6.6 2 mg · wk 5 · n 113 · Phase 2/3 · primary NCT01451164
  • -13.1 vs -11.1 2 mg · wk 4 · n 179 · Phase 3 · primary NCT01393613
  • -12.3 vs -5.7 2 mg · wk 4 · n 113 · Phase 2/3 · primary NCT01451164
  • -10.7 vs -8.9 2 mg · wk 3 · n 179 · Phase 3 · primary NCT01393613
  • -11 vs -6 2 mg · wk 3 · n 113 · Phase 2/3 · primary NCT01451164
  • -8.7 vs -6.6 2 mg · wk 2 · n 179 · Phase 3 · primary NCT01393613
  • -7.9 vs -4.5 2 mg · wk 2 · n 113 · Phase 2/3 · primary NCT01451164
  • -4.3 vs -3.5 2 mg · wk 1 · n 179 · Phase 3 · primary NCT01393613
  • -4.6 vs -3.1 2 mg · wk 1 · n 113 · Phase 2/3 · primary NCT01451164
  • -20 vs -13.5 4 mg · wk 6 · n 181 · Phase 3 · primary NCT01393613
  • -19.6 vs -12.0 4 mg · wk 6 · n 134 · Phase 3 · primary NCT01396421
  • -11.5 vs -7.6 4 mg · wk 6 · n 109 · Phase 2/3 · primary NCT01451164
  • -17.3 vs -11.9 4 mg · wk 5 · n 181 · Phase 3 · primary NCT01393613
  • -11.1 vs -6.6 4 mg · wk 5 · n 109 · Phase 2/3 · primary NCT01451164
  • -15.6 vs -11.1 4 mg · wk 4 · n 181 · Phase 3 · primary NCT01393613
  • -11.2 vs -5.7 4 mg · wk 4 · n 109 · Phase 2/3 · primary NCT01451164
  • -12.6 vs -8.9 4 mg · wk 3 · n 181 · Phase 3 · primary NCT01393613
  • -9.4 vs -6 4 mg · wk 3 · n 109 · Phase 2/3 · primary NCT01451164
  • -8.4 vs -6.6 4 mg · wk 2 · n 181 · Phase 3 · primary NCT01393613
  • -6.8 vs -4.5 4 mg · wk 2 · n 109 · Phase 2/3 · primary NCT01451164
  • -5.6 vs -3.5 4 mg · wk 1 · n 181 · Phase 3 · primary NCT01393613
  • -3.4 vs -3.1 4 mg · wk 1 · n 109 · Phase 2/3 · primary NCT01451164
  • -16.9 vs -13.5 1 mg · wk 6 · n 117 · Phase 3 · primary NCT01393613
  • -8.3 vs -7.6 1 mg · wk 6 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.5 vs -11.9 1 mg · wk 5 · n 117 · Phase 3 · primary NCT01393613
  • -8.1 vs -6.6 1 mg · wk 5 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.0 vs -11.1 1 mg · wk 4 · n 117 · Phase 3 · primary NCT01393613
  • -8.4 vs -5.7 1 mg · wk 4 · n 112 · Phase 2/3 · primary NCT01451164
  • -11.6 vs -8.9 1 mg · wk 3 · n 117 · Phase 3 · primary NCT01393613
  • -6.9 vs -6 1 mg · wk 3 · n 112 · Phase 2/3 · primary NCT01451164
  • -7.6 vs -6.6 1 mg · wk 2 · n 117 · Phase 3 · primary NCT01393613
  • -5.1 vs -4.5 1 mg · wk 2 · n 112 · Phase 2/3 · primary NCT01451164
  • -3.3 vs -3.5 1 mg · wk 1 · n 117 · Phase 3 · primary NCT01393613
  • -2.7 vs -3.1 1 mg · wk 1 · n 112 · Phase 2/3 · primary NCT01451164
  • -14.9 vs -12.0 0.25 mg · wk 6 · n 62 · Phase 3 · primary NCT01396421
  • -22.8 vs -17.4 wk 6 · n 110 · Phase 3 · primary NCT03198078
  • -20 vs -15.9 wk 6 · n 150 · Phase 3 · primary NCT01810380
  • -22.9 vs -19.4 wk 6 · n 64 · Phase 3 · primary NCT02054702
  • -17.9 vs -10.8 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01396421
  • -14.1 vs -8.9 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01396421
  • -11.1 vs -7.6 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01396421
  • -8.9 vs -5.1 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01396421
  • -4.9 vs -2.9 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01396421
  • -18.6 vs -10.8 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -16.5 vs -8.9 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -12.8 vs -7.6 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -9.5 vs -5.1 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -4.4 vs -2.9 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -11.9 vs -10.8 0.25 mg · wk 5 · n 87 · Phase 3 · secondary NCT01396421
  • -8.9 vs -8.9 0.25 mg · wk 4 · n 87 · Phase 3 · secondary NCT01396421
  • -5.7 vs -7.6 0.25 mg · wk 3 · n 87 · Phase 3 · secondary NCT01396421
  • -3.3 vs -5.1 0.25 mg · wk 2 · n 87 · Phase 3 · secondary NCT01396421
  • -2.5 vs -2.9 0.25 mg · wk 1 · n 87 · Phase 3 · secondary NCT01396421
  • 0.6 vs 6.9 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 3.3 vs 11.2 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -2.7 vs 3.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 2.5 vs 10.5 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -1.9 vs 2.9 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 9.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 6.2 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 1.6 vs 6.6 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • 0.8 vs 4.1 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • 0.5 vs 3.6 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -9.8 vs -14.4 0.25 mg · wk 6 · n 41 · Phase 2 · primary NCT00905307
  • -18.7 vs -14.4 Low-dose · wk 6 · n 88 · Phase 2 · primary NCT00905307
  • -16.2 vs -14.4 Mid-dose · wk 6 · n 90 · Phase 2 · primary NCT00905307
  • -18.3 vs -14.4 High-dose · wk 6 · n 92 · Phase 2 · primary NCT00905307
  • -3.7 vs -0.3 wk 12 · n 21 · Phase 4 · secondary NCT03526354

CGI-S, change

Aripiprazole (Abilify)
-1.2 vs -0.9−0.3 vs placebo10 mg/day · wk 6 · n 99NCT00102063
32 other results
  • -1.3 vs -0.9 30 mg/day · wk 6 · n 97 · Phase 3 · secondary NCT00102063
  • 0.1 vs 0.3 wk 52 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 50 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 48 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 46 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 44 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 42 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 40 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 38 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 36 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 34 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 32 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 30 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 28 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 26 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 24 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 22 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.4 wk 20 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 18 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 16 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 14 · n 98 · Phase 3 · secondary NCT01149655
  • 0.1 vs 0.3 wk 12 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.3 wk 10 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.2 wk 8 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 6 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 4 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.1 wk 3 · n 98 · Phase 3 · secondary NCT01149655
  • 0 vs 0.0 wk 2 · n 98 · Phase 3 · secondary NCT01149655
  • 0.0 vs 0.0 wk 1 · n 98 · Phase 3 · secondary NCT01149655
  • -0.8 vs -0.5 wk 28 · n 136 · Phase 3 · secondary NCT01795547
  • -1.3 vs -1.6 wk 6 · n 33 · Phase 3 · secondary NCT02054702
  • -0.1 vs -0.3 wk 104 · n 44 · Phase 3 · secondary NCT00216476
Brexpiprazole (Rexulti)
-1.0 vs -0.8−0.2 vs placebo2 mg · wk 6 · n 180NCT01393613
71 other results
  • -1.1 vs -0.8 2 mg · wk 6 · n 124 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.6 2 mg · wk 6 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 2 mg · wk 5 · n 180 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.7 2 mg · wk 5 · n 181 · Phase 3 · secondary NCT01396421
  • -0.8 vs -0.5 2 mg · wk 5 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 2 mg · wk 4 · n 180 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 2 mg · wk 4 · n 181 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.4 2 mg · wk 4 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 2 mg · wk 3 · n 180 · Phase 3 · secondary NCT01393613
  • -0.6 vs -0.5 2 mg · wk 3 · n 181 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 2 mg · wk 3 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 2 mg · wk 2 · n 180 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.3 2 mg · wk 2 · n 181 · Phase 3 · secondary NCT01396421
  • -0.4 vs -0.3 2 mg · wk 2 · n 113 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 2 mg · wk 1 · n 180 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 2 mg · wk 1 · n 181 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.1 2 mg · wk 1 · n 113 · Phase 2/3 · secondary NCT01451164
  • -1.2 vs -0.8 4 mg · wk 6 · n 183 · Phase 3 · secondary NCT01393613
  • -1.2 vs -0.8 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.6 4 mg · wk 6 · n 109 · Phase 2/3 · secondary NCT01451164
  • -1.0 vs -0.7 4 mg · wk 5 · n 183 · Phase 3 · secondary NCT01393613
  • -1.1 vs -0.7 4 mg · wk 5 · n 178 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 4 mg · wk 5 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.6 4 mg · wk 4 · n 183 · Phase 3 · secondary NCT01393613
  • -1.0 vs -0.5 4 mg · wk 4 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 4 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.4 4 mg · wk 3 · n 183 · Phase 3 · secondary NCT01393613
  • -0.7 vs -0.5 4 mg · wk 3 · n 178 · Phase 3 · secondary NCT01396421
  • -0.5 vs -0.4 4 mg · wk 3 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.4 vs -0.4 4 mg · wk 2 · n 183 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.3 4 mg · wk 2 · n 178 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.3 4 mg · wk 2 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.2 vs -0.1 4 mg · wk 1 · n 183 · Phase 3 · secondary NCT01393613
  • -0.2 vs -0.1 4 mg · wk 1 · n 178 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 4 mg · wk 1 · n 109 · Phase 2/3 · secondary NCT01451164
  • -0.9 vs -0.8 1 mg · wk 6 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.6 1 mg · wk 6 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.7 1 mg · wk 5 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.5 1 mg · wk 5 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.7 vs -0.6 1 mg · wk 4 · n 120 · Phase 3 · secondary NCT01393613
  • -0.5 vs -0.4 1 mg · wk 4 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.6 vs -0.4 1 mg · wk 3 · n 120 · Phase 3 · secondary NCT01393613
  • -0.4 vs -0.4 1 mg · wk 3 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.3 vs -0.4 1 mg · wk 2 · n 120 · Phase 3 · secondary NCT01393613
  • -0.3 vs -0.3 1 mg · wk 2 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.1 vs -0.1 1 mg · wk 1 · n 120 · Phase 3 · secondary NCT01393613
  • -0.1 vs -0.1 1 mg · wk 1 · n 112 · Phase 2/3 · secondary NCT01451164
  • -0.8 vs -0.8 0.25 mg · wk 6 · n 56 · Phase 3 · secondary NCT01396421
  • -0.7 vs -0.7 0.25 mg · wk 5 · n 89 · Phase 3 · secondary NCT01396421
  • -0.6 vs -0.5 0.25 mg · wk 4 · n 89 · Phase 3 · secondary NCT01396421
  • -0.3 vs -0.5 0.25 mg · wk 3 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs -0.3 0.25 mg · wk 2 · n 89 · Phase 3 · secondary NCT01396421
  • -0.1 vs -0.1 0.25 mg · wk 1 · n 89 · Phase 3 · secondary NCT01396421
  • -0.2 vs 0.3 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 0.0 vs 0.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • -0.3 vs 0.3 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • 0 vs 0.6 wk 36 · n 96 · Phase 3 · secondary NCT01668797
  • -0.2 vs 0.2 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.5 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.4 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.0 vs 0.3 wk 12 · n 96 · Phase 3 · secondary NCT01668797
  • -0.9 vs -0.8 wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • -0.0 vs 0.3 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -0.1 vs 0.2 wk 6 · n 96 · Phase 3 · secondary NCT01668797
  • -1.2 vs -0.9 wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • -1.6 vs -1.3 wk 6 · n 64 · Phase 3 · secondary NCT02054702
  • -0.4 vs -0.8 0.25 mg · wk 6 · n 41 · Phase 2 · secondary NCT00905307
  • -1.0 vs -0.8 Low-dose · wk 6 · n 88 · Phase 2 · secondary NCT00905307
  • -0.9 vs -0.8 Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • -1.1 vs -0.8 High-dose · wk 6 · n 92 · Phase 2 · secondary NCT00905307
  • -0.3 vs -0.1 wk 12 · n 21 · Phase 4 · secondary NCT03526354

PANSS response

Aripiprazole (Abilify)
—Not posted · NCT03485417
Brexpiprazole (Rexulti)
38.5% vs 31.7%+6.8 vs placebo2 mg · wk 6 · n 179NCT01393613
8 other results
  • 49.7% vs 31.7% 4 mg · wk 6 · n 181 · Phase 3 · secondary NCT01393613
  • 43.6% vs 31.7% 1 mg · wk 6 · n 117 · Phase 3 · secondary NCT01393613
  • 43.6% vs 28.2% wk 6 · n 110 · Phase 3 · secondary NCT03198078
  • 48.7% vs 32.1% wk 6 · n 150 · Phase 3 · secondary NCT01810380
  • 40.5% vs 49.5% 0.25 mg · wk 6 · n 42 · Phase 2 · secondary NCT00905307
  • 57.3% vs 49.5% Low-dose · wk 6 · n 89 · Phase 2 · secondary NCT00905307
  • 46.7% vs 49.5% Mid-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307
  • 51.6% vs 49.5% High-dose · wk 6 · n 93 · Phase 2 · secondary NCT00905307

PSP, change

Aripiprazole (Abilify)
—Not posted · NCT03485417
Brexpiprazole (Rexulti)
10.5 vs 8.5+2 vs placebo2 mg · wk 6 · n 170NCT01393613
17 other results
  • 13.2 vs 10.3 2 mg · wk 6 · n 122 · Phase 3 · secondary NCT01396421
  • 6.8 vs 5.8 2 mg · wk 3 · n 170 · Phase 3 · secondary NCT01393613
  • 13.1 vs 8.5 4 mg · wk 6 · n 174 · Phase 3 · secondary NCT01393613
  • 12.7 vs 10.3 4 mg · wk 6 · n 121 · Phase 3 · secondary NCT01396421
  • 7.1 vs 5.8 4 mg · wk 3 · n 174 · Phase 3 · secondary NCT01393613
  • 11.7 vs 8.5 1 mg · wk 6 · n 105 · Phase 3 · secondary NCT01393613
  • 7.0 vs 5.8 1 mg · wk 3 · n 105 · Phase 3 · secondary NCT01393613
  • 11.8 vs 10.3 0.25 mg · wk 6 · n 55 · Phase 3 · secondary NCT01396421
  • 18.6 vs 12.6 wk 52 · n 96 · Phase 3 · secondary NCT01668797
  • 15.1 vs 10.3 wk 52 · n 94 · Phase 3 · secondary NCT01668797
  • 18.9 vs 17.8 wk 24 · n 96 · Phase 3 · secondary NCT01668797
  • 15.2 vs 11.4 wk 24 · n 94 · Phase 3 · secondary NCT01668797
  • 13 vs 9.4 wk 6 · n 133 · Phase 3 · secondary NCT01810380
  • 4.5 vs 7.6 0.25 mg · wk 6 · n 39 · Phase 2 · secondary NCT00905307
  • 11.4 vs 7.6 Low-dose · wk 6 · n 86 · Phase 2 · secondary NCT00905307
  • 10.7 vs 7.6 Mid-dose · wk 6 · n 84 · Phase 2 · secondary NCT00905307
  • 12.2 vs 7.6 High-dose · wk 6 · n 90 · Phase 2 · secondary NCT00905307

Relapse (% of patients)

Aripiprazole (Abilify)
19.4% vs 37.5%−18.1 vs placebowk 52 · n 98NCT01149655
1 other result
  • 10% vs 39.6% wk 52 · n 269 · Phase 3 · secondary NCT00705783
Brexpiprazole (Rexulti)
13.5% vs 38.5%−24.9 vs placebowk 52 · n 96NCT01668797
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
21 other shared endpoints and safety

Coverage. Aripiprazole (Abilify): 25 of 25 rows · Brexpiprazole (Rexulti): 25 of 25 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAripiprazole (Abilify)
Rows use multiple source trials
Brexpiprazole (Rexulti)
Rows use multiple source trials
BMI
absolute change · kg
-0.52 vs 0.03 placebo kg @ 8wka,b,c,d
NCT00345033 · Phase 4 · registry result, not featured evidence
0.2 vs 0 placebo kg @ 6wka,b,c,d
NCT03198078 · Phase 3
CGAS
absolute change · score
0.4 vs -2.08 placebo score @ 6wkb,c
NCT01149655 · Phase 3 · registry result, not featured evidence
10.56 vs 8.08 placebo score @ 6wkb,c
NCT03198078 · Phase 3
CGAS
absolute change · score
No placebo or comparator arm
5.6 score @ 52wkb,c,e
NCT01942148 · Phase 3 · registry result, not featured evidence
23.05 scoref,b,c,e
NCT03238326 · Phase 3
show 3 more doses
13.58 score
NCT03238326 · Phase 3
14.31 score
NCT03238326 · Phase 3
12.92 score
NCT03238326 · Phase 3
CGI-I
absolute change · score
2.7 vs 2.5 Brexpiprazole score @ 6wkb,c
NCT02054702 · Phase 3 · registry result, not featured evidence
2.5 vs 2.7 Aripiprazole score @ 6wkb,c
NCT02054702 · Phase 3 · registry result, not featured evidence
CGI-I
absolute value · score
3.42 vs 3.92 placebo score @ 52wkb,c
NCT01149655 · Phase 3 · registry result, not featured evidence
3.77 vs 4.4 placebo score @ 52wkb,c
NCT01668797 · Phase 3
CGI-I
absolute value · score
No placebo or comparator arm
3.25 score @ 52wk400/300 mg IM Depotb,c,e
NCT00731549 · Phase 3 · registry result, not featured evidence
1.9 scoref,b,c,e
NCT03238326 · Phase 3
show 3 more doses
2.1 score
NCT03238326 · Phase 3
2.1 score
NCT03238326 · Phase 3
2.2 score
NCT03238326 · Phase 3
CGI-I
absolute change · score
No placebo or comparator arm
2.7 score @ 6.14wk24-30 mg/dayf,g,b,c,h
NCT01942161 · Phase 2/3 · registry result, not featured evidence
show 2 more doses
3.2 score @ 6.14wk6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
3 score @ 6.14wk2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
3.5 score @ 1.57wk4 mgf,g,b,c,h
NCT01854944 · Phase 1 · registry result, not featured evidence
show 2 more doses
2.7 score @ 1.57wk4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
3.8 score @ 1.57wk1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
CGI-S
absolute change · score
No placebo or comparator arm
-0.3 score @ 52wkb,c
NCT01942148 · Phase 3 · registry result, not featured evidence
3 other source trials
-0.24 score @ 52wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
2.3 score @ 52wk10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
1.1 score @ 52wk5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
-0.48 score @ 52wkf,b,c
NCT01397786 · Phase 3 · registry result, not featured evidence
show 2 more doses
-0.55 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
-0.97 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
Cognitive Composite Z Score
absolute change · Z-score
-0.024 vs 0.045 Brexpiprazole Z-score @ 6wkf,b,c
NCT02054702 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.113 vs -0.01 Brexpiprazole Z-score @ 6wk
NCT02054702 · Phase 3 · registry result, not featured evidence
0.045 vs -0.024 Aripiprazole Z-score @ 6wkf,b,c
NCT02054702 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.01 vs 0.113 Aripiprazole Z-score @ 6wk
NCT02054702 · Phase 3 · registry result, not featured evidence
Overall
responder rate · % of participants
48.5% (n=33) vs 60.9% (n=64) Brexpiprazole @ 6wkb,c
NCT02054702 · Phase 3 · registry result, not featured evidence
47.78% (n=180) vs 30.34% (n=178) placebo @ 6wk2 mgf,b,c
NCT01396421 · Phase 3
show 2 more doses
46.07% (n=178) vs 30.34% (n=178) placebo @ 6wk4 mg
NCT01396421 · Phase 3
39.08% (n=87) vs 30.34% (n=178) placebo @ 6wk0.25 mg
NCT01396421 · Phase 3
PANSS Negative
absolute change · score
No placebo or comparator arm
-0.96 score @ 4wk400mgf,i,b,c,j
NCT01552772 · Phase 1 · registry result, not featured evidence
show 1 more dose
-0.92 score @ 4wk400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
-2 score @ 52wkf,i,b,c,j
NCT01397786 · Phase 3 · registry result, not featured evidence
show 2 more doses
-2.7 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
-3.7 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
PANSS Negative Subscale
absolute change · score
-0.78 vs 0.4 placebo score @ 52wkb,c
NCT01149655 · Phase 3 · registry result, not featured evidence
1.3 vs 0.87 placebo score @ 52wkf,b,c
NCT01668797 · Phase 3
show 1 more dose
0.39 vs 1.63 placebo score @ 52wk
NCT01668797 · Phase 3
PANSS Negative Subscale
absolute change · score
No placebo or comparator arm
-1.6 score @ 24wkb,c,e
NCT01432444 · Phase 3 · registry result, not featured evidence
-4.4 scoref,b,c,e
NCT03238326 · Phase 3
show 3 more doses
-4.82 score
NCT03238326 · Phase 3
-4.89 score
NCT03238326 · Phase 3
-4.55 score
NCT03238326 · Phase 3
PANSS Positive
absolute change · score
No placebo or comparator arm
-1.28 score @ 4wk400mgf,i,b,c,j
NCT01552772 · Phase 1 · registry result, not featured evidence
show 1 more dose
-1.25 score @ 4wk400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
-2.3 score @ 52wkf,i,b,c,j
NCT01397786 · Phase 3 · registry result, not featured evidence
show 2 more doses
-3.2 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
-5.8 score @ 52wk
NCT01397786 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale
absolute change · score
0.16 vs 2.31 placebo score @ 52wkb,c
NCT01149655 · Phase 3 · registry result, not featured evidence
-1.21 vs 1.5 placebo score @ 52wkf,b,c
NCT01668797 · Phase 3
show 1 more dose
0.99 vs 4.17 placebo score @ 52wk
NCT01668797 · Phase 3
PANSS Positive Subscale
absolute change · score
No placebo or comparator arm
-3 score @ 24wkb,c,e
NCT01432444 · Phase 3 · registry result, not featured evidence
-5.15 scoref,b,c,e
NCT03238326 · Phase 3
show 3 more doses
-4.59 score
NCT03238326 · Phase 3
-5.2 score
NCT03238326 · Phase 3
-5.29 score
NCT03238326 · Phase 3
PANSS Total
absolute change · score
No placebo or comparator arm
-7.9 score @ 52wkb,c,e
NCT01942148 · Phase 3 · registry result, not featured evidence
1 other source trial
-3.55 score @ 52wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
-19 scoref,b,c,e
NCT03238326 · Phase 3
show 3 more doses
-18.44 score
NCT03238326 · Phase 3
-20.14 score
NCT03238326 · Phase 3
-19.76 score
NCT03238326 · Phase 3
QLS Total
absolute change · score
7.47 vs 2.8 Paliperidone score @ 28wkk,b,c,l
NCT01795547 · Phase 3 · registry result, not featured evidence
4.049 vs -5.146 Treatment as Usual score @ 12wkk,b,c,l
NCT03526354 · Phase 4 · registry result, not featured evidence
Remission
responder rate · % of participants
43.8% (n=48) vs 42.1% (n=19) placebo @ 52wkb,c,m
NCT01149655 · Phase 3 · registry result, not featured evidence
29.09% (n=110) vs 23.3% (n=103) placebo @ 6wkb,c,m
NCT03198078 · Phase 3
SLOF Total
absolute change · score
6 vs 7.5 Brexpiprazole score @ 6wkb,c
NCT02054702 · Phase 3 · registry result, not featured evidence
7.5 vs 6 Aripiprazole score @ 6wkb,c
NCT02054702 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
-1.5 vs 0.3 placebo kg @ 8wka,b,c,d
NCT00345033 · Phase 4 · registry result, not featured evidence
0.8 vs 0 placebo kg @ 6wka,b,c,d
NCT03198078 · Phase 3
Dropout rate
20%n
NCT00345033 · Phase 4 · registry result, not featured evidence
show 30 more results
39.7%
NCT01942148 · Phase 3 · registry result, not featured evidence
12.5%
NCT01959035 · Phase 3 · registry result, not featured evidence
32.4%
NCT01795547 · Phase 3 · registry result, not featured evidence
36.4%
NCT02054702 · Phase 3 · registry result, not featured evidence
—
NCT01149655 · Phase 3 · registry result, not featured evidence
—
NCT01432444 · Phase 3 · registry result, not featured evidence
20.6%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
40.2%10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
45%5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—300 or 400 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
—25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
84.7%
NCT01001702 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot
NCT00705783 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · registry result, not featured evidence
37.8%
NCT00216476 · Phase 3 · registry result, not featured evidence
26.8%
NCT00102518 · Phase 3 · registry result, not featured evidence
16%10 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
17.6%30 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
14.6%24-30 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
20%6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
22.9%2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
11.1%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
26.3%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
6.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
16.7%
NCT01338298 · Phase na · registry result, not featured evidence
30.6%2 mgn
NCT01393613 · Phase 3
show 45 more results
29.3%4 mg
NCT01393613 · Phase 3
32.5%1 mg
NCT01393613 · Phase 3
—2 mg
NCT01396421 · Phase 3
31.9%2 mg
NCT01396421 · Phase 3
32.8%4 mg
NCT01396421 · Phase 3
—4 mg
NCT01396421 · Phase 3
—0.25 mg
NCT01396421 · Phase 3
37.8%0.25 mg
NCT01396421 · Phase 3
0%De Novo (Conversion Period)
NCT03238326 · Phase 3
—De Novo (OLT Period)
NCT03238326 · Phase 3
—Prior & Current Brexpiprazole (OLT
NCT03238326 · Phase 3
—Prior Aripiprazole & Current Brexp
NCT03238326 · Phase 3
—Prior Placebo & Current Brexpipraz
NCT03238326 · Phase 3
—Prior and Current Brexpiprazole
NCT03238326 · Phase 3
2.7%
NCT03198078 · Phase 3
—
NCT01668797 · Phase 3
28.6%
NCT03526354 · Phase 4 · registry result, not featured evidence
15.8%2 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
47.4%4 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
12.3%De Novo
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase A)
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
0%Prior Brexpiprazole
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Brexpiprazole (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
51.9%
NCT01810783 · Phase 3 · registry result, not featured evidence
25.2%
NCT01810380 · Phase 3 · registry result, not featured evidence
49%
NCT02013622 · Phase 3 · registry result, not featured evidence
37.5%
NCT02054702 · Phase 3 · registry result, not featured evidence
29.6%2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
39.8%4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
37.4%1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
52.4%0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
—High-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
41.6%Low-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
41.1%Mid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
—Fasted Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
—Fed Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
0%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
25%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
0%1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
14.9%4 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
27.4%12 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
—3mg
NCT01289080 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—n
NCT00345033 · Phase 4 · registry result, not featured evidence
show 30 more results
5.9%
NCT01942148 · Phase 3 · registry result, not featured evidence
5.7%
NCT01959035 · Phase 3 · registry result, not featured evidence
10.8%
NCT01795547 · Phase 3 · registry result, not featured evidence
3%
NCT02054702 · Phase 3 · registry result, not featured evidence
—
NCT01149655 · Phase 3 · registry result, not featured evidence
—
NCT01432444 · Phase 3 · registry result, not featured evidence
2.9%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
6.2%10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
0%5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—300 or 400 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
—25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
8.2%
NCT01001702 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot
NCT00705783 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · registry result, not featured evidence
2.2%
NCT00216476 · Phase 3 · registry result, not featured evidence
—
NCT00102518 · Phase 3 · registry result, not featured evidence
7%10 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
3.9%30 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
12.2%24-30 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
6.7%6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
2.9%2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
—30 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
—20 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
—
NCT01338298 · Phase na · registry result, not featured evidence
5.9%2 mgn
NCT01393613 · Phase 3
show 45 more results
7.1%4 mg
NCT01393613 · Phase 3
9.2%1 mg
NCT01393613 · Phase 3
—2 mg
NCT01396421 · Phase 3
8.2%2 mg
NCT01396421 · Phase 3
9.4%4 mg
NCT01396421 · Phase 3
—4 mg
NCT01396421 · Phase 3
—0.25 mg
NCT01396421 · Phase 3
13.3%0.25 mg
NCT01396421 · Phase 3
—De Novo (Conversion Period)
NCT03238326 · Phase 3
—De Novo (OLT Period)
NCT03238326 · Phase 3
—Prior & Current Brexpiprazole (OLT
NCT03238326 · Phase 3
—Prior Aripiprazole & Current Brexp
NCT03238326 · Phase 3
—Prior Placebo & Current Brexpipraz
NCT03238326 · Phase 3
—Prior and Current Brexpiprazole
NCT03238326 · Phase 3
0%
NCT03198078 · Phase 3
—
NCT01668797 · Phase 3
—
NCT03526354 · Phase 4 · registry result, not featured evidence
—2 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
—4 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
3.5%De Novo
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase A)
NCT01397786 · Phase 3 · registry result, not featured evidence
—De Novo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
0%Prior Brexpiprazole
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Brexpiprazole (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
15.2%
NCT01810783 · Phase 3 · registry result, not featured evidence
9.3%
NCT01810380 · Phase 3 · registry result, not featured evidence
6.1%
NCT02013622 · Phase 3 · registry result, not featured evidence
4.7%
NCT02054702 · Phase 3 · registry result, not featured evidence
10.4%2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
15.9%4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
16.5%1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
7.1%0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
—High-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
4.5%Low-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
5.6%Mid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
—Fasted Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
—Fed Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
—4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
—4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
—1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
6.8%4 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
12.3%12 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
—3mg
NCT01289080 · Phase 1 · registry result, not featured evidence
Serious AEs
0%n
NCT00345033 · Phase 4 · registry result, not featured evidence
show 30 more results
10.3%
NCT01942148 · Phase 3 · registry result, not featured evidence
3.4%
NCT01959035 · Phase 3 · registry result, not featured evidence
8.3%
NCT01795547 · Phase 3 · registry result, not featured evidence
3%
NCT02054702 · Phase 3 · registry result, not featured evidence
3.1%
NCT01149655 · Phase 3 · registry result, not featured evidence
14.2%
NCT01432444 · Phase 3 · registry result, not featured evidence
8.8%400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
—10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
—5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
0%5 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
13.4%10 - 30 mg QD
NCT00239356 · Phase 3 · registry result, not featured evidence
5.7%300 or 400 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
8.4%25 or 50 mg
NCT00706654 · Phase 3 · registry result, not featured evidence
12.9%
NCT01001702 · Phase 3 · registry result, not featured evidence
—Aripiprazole Depot
NCT00705783 · Phase 3 · registry result, not featured evidence
4.1%Aripiprazole Depot - Depot Mainten
NCT00705783 · Phase 3 · registry result, not featured evidence
15.6%
NCT00216476 · Phase 3 · registry result, not featured evidence
6.2%
NCT00102518 · Phase 3 · registry result, not featured evidence
4%10 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
3.9%30 mg/day
NCT00102063 · Phase 3 · registry result, not featured evidence
4.9%24-30 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
6.7%6-12 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
0%2 mg/day
NCT01942161 · Phase 2/3 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01646827 · Phase 1 · registry result, not featured evidence
1.7%400mg
NCT01552772 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT00102479 · Phase 1 · registry result, not featured evidence
0%
NCT01338298 · Phase na · registry result, not featured evidence
2.2%2 mgn
NCT01393613 · Phase 3
show 45 more results
2.2%4 mg
NCT01393613 · Phase 3
2.5%1 mg
NCT01393613 · Phase 3
2.2%2 mg
NCT01396421 · Phase 3
—2 mg
NCT01396421 · Phase 3
—4 mg
NCT01396421 · Phase 3
1.1%4 mg
NCT01396421 · Phase 3
4.4%0.25 mg
NCT01396421 · Phase 3
—0.25 mg
NCT01396421 · Phase 3
0%De Novo (Conversion Period)
NCT03238326 · Phase 3
5%De Novo (OLT Period)
NCT03238326 · Phase 3
—Prior & Current Brexpiprazole (OLT
NCT03238326 · Phase 3
1.1%Prior Aripiprazole & Current Brexp
NCT03238326 · Phase 3
3.4%Prior Placebo & Current Brexpipraz
NCT03238326 · Phase 3
4.1%Prior and Current Brexpiprazole
NCT03238326 · Phase 3
0.9%
NCT03198078 · Phase 3
3.1%
NCT01668797 · Phase 3
0%
NCT03526354 · Phase 4 · registry result, not featured evidence
0%2 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
0%4 mg
NCT02194933 · Phase 3 · registry result, not featured evidence
—De Novo
NCT01397786 · Phase 3 · registry result, not featured evidence
1.8%De Novo (Phase A)
NCT01397786 · Phase 3 · registry result, not featured evidence
11.2%De Novo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Brexpiprazole
NCT01397786 · Phase 3 · registry result, not featured evidence
14.9%Prior Brexpiprazole (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
—Prior Placebo
NCT01397786 · Phase 3 · registry result, not featured evidence
8.9%Prior Placebo (Phase B)
NCT01397786 · Phase 3 · registry result, not featured evidence
14.8%
NCT01810783 · Phase 3 · registry result, not featured evidence
4.7%
NCT01810380 · Phase 3 · registry result, not featured evidence
0%
NCT02013622 · Phase 3 · registry result, not featured evidence
4.7%
NCT02054702 · Phase 3 · registry result, not featured evidence
4.4%2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
4.4%4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
7%1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
0%0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
4.3%High-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
3.4%Low-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
5.6%Mid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
0%Fasted Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
1.8%Fed Stated
NCT06036108 · Phase 1 · registry result, not featured evidence
0%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
0%4 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
0%1 mg
NCT01854944 · Phase 1 · registry result, not featured evidence
1.4%4 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
0%12 mg
NCT01423916 · Phase 1 · registry result, not featured evidence
0%3mg
NCT01289080 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
n
eye irritation/swelling 6.3% (placebo 0%)
psychiatric decompensation 6.3% (placebo 0%)
psychiatric decompensation 6.3% (placebo 0%)
NCT00345033 · Phase 4 · registry result, not featured evidence
show 27 more results
nasopharyngitis 45.6%
somnolence 20.6%
nausea 17.6%
NCT01942148 · Phase 3 · registry result, not featured evidence
weight increased 6.8%
NCT01959035 · Phase 3 · registry result, not featured evidence
accidental overdose 20.8%
insomnia 11.8%
weight increased 9%
NCT01795547 · Phase 3 · registry result, not featured evidence
akathisia 21.2%
headache 12.1%
constipation 9.1%
NCT02054702 · Phase 3 · registry result, not featured evidence
schizophrenia 9.2% (placebo 16.7%)
weight increased 8.2% (placebo 10.4%)
nasopharyngitis 7.1% (placebo 2.1%)
NCT01149655 · Phase 3 · registry result, not featured evidence
insomnia 6.7%
akathisia 6.3%
weight increased 2.3%
NCT01432444 · Phase 3 · registry result, not featured evidence
400/300 mg IM Depot
headache 7.6%
nasopharyngitis 7%
anxiety 6.8%
NCT00731549 · Phase 3 · registry result, not featured evidence
5 - 30 mg QD
pyrexia 35%
headache 30%
cough 15%
NCT00239356 · Phase 3 · registry result, not featured evidence
10 - 30 mg QD
back pain 7.2%
anxiety 6.2%
headache 6.2%
NCT00239356 · Phase 3 · registry result, not featured evidence
300 or 400 mg
insomnia 11.7%
akathisia 10.6%
headache 9.8%
NCT00706654 · Phase 3 · registry result, not featured evidence
25 or 50 mg
insomnia 13.7%
back pain 11.5%
weight decreased 9.2%
NCT00706654 · Phase 3 · registry result, not featured evidence
headache 15.3%
influenza 10.6%
weight increased 10.6%
NCT01001702 · Phase 3 · registry result, not featured evidence
insomnia 10% (placebo 9%)
weight increased 9.7% (placebo 9.7%)
anxiety 5.9% (placebo 7.5%)
NCT00705783 · Phase 3 · registry result, not featured evidence
insomnia 24.4%
anxiety 15.6%
headache 11.1%
NCT00216476 · Phase 3 · registry result, not featured evidence
extrapyramidal disorder 14.8%
somnolence 12.9%
headache 9.5%
NCT00102518 · Phase 3 · registry result, not featured evidence
10 mg/day
headache 16% (placebo 10%)
extrapyramidal disorder 13% (placebo 5%)
insomnia 11% (placebo 15%)
NCT00102063 · Phase 3 · registry result, not featured evidence
30 mg/day
extrapyramidal disorder 21.6% (placebo 5%)
somnolence 21.6% (placebo 6%)
tremor 11.8% (placebo 2%)
NCT00102063 · Phase 3 · registry result, not featured evidence
24-30 mg/day
nausea 22%
insomnia 17.1%
salivary hypersecretion 14.6%
NCT01942161 · Phase 2/3 · registry result, not featured evidence
6-12 mg/day
insomnia 20%
somnolence 20%
epistaxis 13.3%
NCT01942161 · Phase 2/3 · registry result, not featured evidence
2 mg/day
nausea 20%
insomnia 14.3%
nasopharyngitis 14.3%
NCT01942161 · Phase 2/3 · registry result, not featured evidence
400 mg
injection site pain 35.3%
headache 23.5%
akathisia 17.6%
NCT01646827 · Phase 1 · registry result, not featured evidence
400 mg
injection site pain 27.8%
headache 22.2%
akathisia 16.7%
NCT01646827 · Phase 1 · registry result, not featured evidence
400mg
injection site pain 6.7%
toothache 6.7%
blood creatine phosphokinase increased 5%
NCT01552772 · Phase 1 · registry result, not featured evidence
30 mg
headache 50%
sedation 33.3%
abdominal pain upper 16.7%
NCT00102479 · Phase 1 · registry result, not featured evidence
25 mg
abdominal pain upper 42.9%
acne 28.6%
dizziness 28.6%
NCT00102479 · Phase 1 · registry result, not featured evidence
20 mg
headache 50%
insomnia 25%
musculoskeletal stiffness 25%
NCT00102479 · Phase 1 · registry result, not featured evidence
nausea 50% (placebo 22.2%)
vomiting 50% (placebo 38.9%)
diarrhea 45% (placebo 38.9%)
NCT01338298 · Phase na · registry result, not featured evidence
2 mgn
insomnia 13.4% (placebo 14.7%)
headache 10.8% (placebo 14.7%)
agitation 8.6% (placebo 7.1%)
NCT01393613 · Phase 3
show 38 more results
4 mg
insomnia 15.2% (placebo 14.7%)
headache 10.3% (placebo 14.7%)
agitation 7.1% (placebo 7.1%)
NCT01393613 · Phase 3
1 mg
insomnia 12.5% (placebo 14.7%)
agitation 8.3% (placebo 7.1%)
headache 7.5% (placebo 14.7%)
NCT01393613 · Phase 3
2 mg
headache 9.3% (placebo 8.2%)
insomnia 8.8% (placebo 9.8%)
agitation 6% (placebo 10.3%)
NCT01396421 · Phase 3
4 mg
headache 12.2% (placebo 8.2%)
insomnia 8.3% (placebo 9.8%)
agitation 7.2% (placebo 10.3%)
NCT01396421 · Phase 3
0.25 mg
headache 10% (placebo 8.2%)
insomnia 8.9% (placebo 9.8%)
schizophrenia 6.7% (placebo 9.8%)
NCT01396421 · Phase 3
irritability 14.3%
somnolence 14.3%
akathisia 7.1%
NCT03238326 · Phase 3
somnolence 30%
weight increased 20%
coronavirus test positive 10%
NCT03238326 · Phase 3
weight increased 13.5%
headache 10.1%
somnolence 7.9%
NCT03238326 · Phase 3
headache 12.6%
somnolence 10.3%
weight increased 10.3%
NCT03238326 · Phase 3
headache 10.2%
nasopharyngitis 9.2%
somnolence 9.2%
NCT03238326 · Phase 3
headache 6.4% (placebo 4.8%)
nausea 6.4% (placebo 3.8%)
somnolence 4.5% (placebo 4.8%)
NCT03198078 · Phase 3
agitation 0% (placebo 0%)
akathisia 0% (placebo 0%)
headache 0% (placebo 0%)
NCT01668797 · Phase 3
fatigure/tiredness 14.3%
nausea 14.3%
cold-like symptoms 9.5%
NCT03526354 · Phase 4 · registry result, not featured evidence
2 mg
headache 15.8%
insomnia 10.5%
irritability 10.5%
NCT02194933 · Phase 3 · registry result, not featured evidence
4 mg
agitation 10.5%
anxiety 10.5%
back pain 10.5%
NCT02194933 · Phase 3 · registry result, not featured evidence
agitation 0%
akathisia 0%
headache 0%
NCT01397786 · Phase 3 · registry result, not featured evidence
insomnia 12.5%
headache 9.4%
agitation 9%
NCT01397786 · Phase 3 · registry result, not featured evidence
insomnia 8.4%
weight increased 7.8%
headache 6.9%
NCT01397786 · Phase 3 · registry result, not featured evidence
insomnia 8.4%
weight increased 7.4%
akathisia 6.9%
NCT01397786 · Phase 3 · registry result, not featured evidence
weight increased 10.5%
headache 8.6%
insomnia 8.1%
NCT01810783 · Phase 3 · registry result, not featured evidence
insomnia 8.7% (placebo 6.2%)
akathisia 6% (placebo 2.5%)
headache 5.3% (placebo 6.8%)
NCT01810380 · Phase 3 · registry result, not featured evidence
insomnia 14.3%
somnolence 8.2%
nausea 6.1%
NCT02013622 · Phase 3 · registry result, not featured evidence
akathisia 9.4%
weight increased 9.4%
dry mouth 7.8%
NCT02054702 · Phase 3 · registry result, not featured evidence
2 mg
schizophrenia 11.4% (placebo 24.1%)
headache 7.9% (placebo 4.3%)
constipation 7% (placebo 7.8%)
NCT01451164 · Phase 2/3 · registry result, not featured evidence
4 mg
schizophrenia 20.4% (placebo 24.1%)
nasopharyngitis 8.8% (placebo 9.5%)
vomiting 7.1% (placebo 3.4%)
NCT01451164 · Phase 2/3 · registry result, not featured evidence
1 mg
schizophrenia 17.4% (placebo 24.1%)
nasopharyngitis 10.4% (placebo 9.5%)
constipation 7% (placebo 7.8%)
NCT01451164 · Phase 2/3 · registry result, not featured evidence
0.25 mg
headache 14.3% (placebo 10.5%)
anxiety 11.9% (placebo 10.5%)
agitation 9.5% (placebo 4.2%)
NCT00905307 · Phase 2 · registry result, not featured evidence
High-dose
akathisia 15.1% (placebo 4.2%)
anxiety 10.8% (placebo 10.5%)
insomnia 9.7% (placebo 16.8%)
NCT00905307 · Phase 2 · registry result, not featured evidence
Low-dose
insomnia 13.5% (placebo 16.8%)
headache 9% (placebo 10.5%)
anxiety 7.9% (placebo 10.5%)
NCT00905307 · Phase 2 · registry result, not featured evidence
Mid-dose
headache 14.4% (placebo 10.5%)
insomnia 10% (placebo 16.8%)
weight increased 10% (placebo 3.2%)
NCT00905307 · Phase 2 · registry result, not featured evidence
nausea 9.6%
somnolence 9.6%
diarrhoea 5.8%
NCT06036108 · Phase 1 · registry result, not featured evidence
vomiting 20%
nausea 12.7%
somnolence 12.7%
NCT06036108 · Phase 1 · registry result, not featured evidence
4 mg
abdominal pain 25%
akathisia 25%
blepharospasm 25%
NCT01854944 · Phase 1 · registry result, not featured evidence
4 mg
akathisia 25%
dental carries 25%
dyspepsia 25%
NCT01854944 · Phase 1 · registry result, not featured evidence
1 mg
abdominal discomfort 50%
agitation 25%
abdominal pain 0%
NCT01854944 · Phase 1 · registry result, not featured evidence
4 mg
nausea 10% (placebo 5.9%)
application site dermatitis 8.6% (placebo 5.9%)
dizziness 8.6% (placebo 1.5%)
NCT01423916 · Phase 1 · registry result, not featured evidence
12 mg
dizziness 11.9% (placebo 1.5%)
akathisia 7.5% (placebo 1.5%)
extrapyramidal disorder 7.5% (placebo 1.5%)
NCT01423916 · Phase 1 · registry result, not featured evidence
3mg
somnolence 15.8%
headache 10.5%
orthostatic hypotension 10.5%
NCT01289080 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 6 weeks versus 8 weeks.
  5. eThe assessment timepoint is not available for both results.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gTrial phases differ: Phase 1 versus Phase 2/3.
  8. hAssessment timepoints differ: 1.57 weeks versus 6.14 weeks.
  9. iTrial phases differ: Phase 3 versus Phase 1.
  10. jAssessment timepoints differ: 52 weeks versus 4 weeks.
  11. kTrial phases differ: Phase 4 versus Phase 3.
  12. lAssessment timepoints differ: 12 weeks versus 28 weeks.
  13. mAssessment timepoints differ: 6 weeks versus 52 weeks.
  14. nPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aripiprazole (Abilify)

Total Cholesterol Change mg/dL -15.3 vs 5.6 placebo mg/dL @ 8wk
absolute change · mg/dL
NCT00345033 · Phase 4 · registry result, not featured evidence
Insulin Sensitivity 0.003 vs -0.005 placebo minutes @ 8wk
absolute change · minutes
NCT00345033 · Phase 4 · registry result, not featured evidence
Triglyceride Change mg/dL -5.9 vs -7.3 placebo mg/dL @ 8wk
absolute change · mg/dL
NCT00345033 · Phase 4 · registry result, not featured evidence
HOMA-IR 0.6 vs 0.65 placebo score @ 8wk
absolute change · score
NCT00345033 · Phase 4 · registry result, not featured evidence
SWN-K Total 0.19 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01959035 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.57 score @ 12wk
NCT01959035 · Phase 3 · registry result, not featured evidence
QLS Total 2.32 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01959035 · Phase 3 · registry result, not featured evidence
show 1 more result
2.08 score @ 12wk
NCT01959035 · Phase 3 · registry result, not featured evidence
SWN-K Total 4.82 vs 3.81 Paliperidone score @ 28wk
absolute change · score
NCT01795547 · Phase 3 · registry result, not featured evidence
Relapse 19.39% (n=98) vs 37.5% (n=48) placebo @ 52wk
event count · % of participants
NCT01149655 · Phase 3 · registry result, not featured evidence
Responder 96.8% (n=98) vs 97.8% (n=48) placebo @ 1wk
responder rate · % of participants
NCT01149655 · Phase 3 · registry result, not featured evidence
show 27 more results
92.3% (n=98) vs 95.7% (n=48) placebo @ 2wk
NCT01149655 · Phase 3 · registry result, not featured evidence
93% (n=98) vs 86.7% (n=48) placebo @ 3wk
NCT01149655 · Phase 3 · registry result, not featured evidence
93.4% (n=98) vs 90.7% (n=48) placebo @ 4wk
NCT01149655 · Phase 3 · registry result, not featured evidence
90.8% (n=98) vs 92.7% (n=48) placebo @ 6wk
NCT01149655 · Phase 3 · registry result, not featured evidence
97.6% (n=98) vs 89.5% (n=48) placebo @ 8wk
NCT01149655 · Phase 3 · registry result, not featured evidence
94.6% (n=98) vs 93.8% (n=48) placebo @ 10wk
NCT01149655 · Phase 3 · registry result, not featured evidence
94.4% (n=98) vs 93.3% (n=48) placebo @ 12wk
NCT01149655 · Phase 3 · registry result, not featured evidence
94.1% (n=98) vs 92.3% (n=48) placebo @ 14wk
NCT01149655 · Phase 3 · registry result, not featured evidence
96.9% (n=98) vs 96% (n=48) placebo @ 16wk
NCT01149655 · Phase 3 · registry result, not featured evidence
94.9% (n=98) vs 91.3% (n=48) placebo @ 18wk
NCT01149655 · Phase 3 · registry result, not featured evidence
94.7% (n=98) vs 91.3% (n=48) placebo @ 20wk
NCT01149655 · Phase 3 · registry result, not featured evidence
92.7% (n=98) vs 95.2% (n=48) placebo @ 22wk
NCT01149655 · Phase 3 · registry result, not featured evidence
98% (n=98) vs 100% (n=48) placebo @ 24wk
NCT01149655 · Phase 3 · registry result, not featured evidence
97.9% (n=98) vs 100% (n=48) placebo @ 26wk
NCT01149655 · Phase 3 · registry result, not featured evidence
97.6% (n=98) vs 100% (n=48) placebo @ 28wk
NCT01149655 · Phase 3 · registry result, not featured evidence
95% (n=98) vs 100% (n=48) placebo @ 30wk
NCT01149655 · Phase 3 · registry result, not featured evidence
94.9% (n=98) vs 93.8% (n=48) placebo @ 32wk
NCT01149655 · Phase 3 · registry result, not featured evidence
94.7% (n=98) vs 100% (n=48) placebo @ 34wk
NCT01149655 · Phase 3 · registry result, not featured evidence
94.4% (n=98) vs 100% (n=48) placebo @ 36wk
NCT01149655 · Phase 3 · registry result, not featured evidence
100% (n=98) vs 100% (n=48) placebo @ 38wk
NCT01149655 · Phase 3 · registry result, not featured evidence
100% (n=98) vs 100% (n=48) placebo @ 40wk
NCT01149655 · Phase 3 · registry result, not featured evidence
100% (n=98) vs 100% (n=48) placebo @ 42wk
NCT01149655 · Phase 3 · registry result, not featured evidence
100% (n=98) vs 100% (n=48) placebo @ 44wk
NCT01149655 · Phase 3 · registry result, not featured evidence
88.9% (n=98) vs 100% (n=48) placebo @ 46wk
NCT01149655 · Phase 3 · registry result, not featured evidence
94.1% (n=98) vs 100% (n=48) placebo @ 48wk
NCT01149655 · Phase 3 · registry result, not featured evidence
88.2% (n=98) vs 100% (n=48) placebo @ 50wk
NCT01149655 · Phase 3 · registry result, not featured evidence
100% (n=98) vs 100% (n=48) placebo @ 52wk
NCT01149655 · Phase 3 · registry result, not featured evidence
Responder 77.6% (n=98) vs 64.6% (n=48) placebo @ 52wk
responder rate · % of participants
Last Visit (N= 98, 48)
NCT01149655 · Phase 3 · registry result, not featured evidence
Psychiatric Hospitalization 2.7% (n=336) @ 26wk
event count · % of participants
No placebo or comparator arm
Prospective period
NCT01432444 · Phase 3 · registry result, not featured evidence · converted to % from 9 participants as posted
Relapse Free 99.02% (n=1081) @ 2wk400/300 mg IM Depot
responder rate · % of participants
No placebo or comparator arm
NCT00731549 · Phase 3 · registry result, not featured evidence
show 14 more results
99.14% (n=1081) @ 4wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
98.51% (n=1081) @ 8wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
97.47% (n=1081) @ 12wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
98.42% (n=1081) @ 16wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
98.15% (n=1081) @ 20wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
99.2% (n=1081) @ 24wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
98.95% (n=1081) @ 28wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
99.16% (n=1081) @ 32wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
99.26% (n=1081) @ 36wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
99.5% (n=1081) @ 40wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
99.11% (n=1081) @ 44wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
99.2% (n=1081) @ 48wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
98.96% (n=1081) @ 52wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence
98.95% (n=1081) @ 28wk400/300 mg IM Depot
NCT00731549 · Phase 3 · registry result, not featured evidence

+ 30 further endpoints in the CSV export.

Brexpiprazole (Rexulti)

PSP 6.85 vs 5.8 placebo score @ 3wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 17 more results
10.52 vs 8.52 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
13.15 vs 10.26 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
7.12 vs 5.8 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
13.11 vs 8.52 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
12.72 vs 10.26 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
6.97 vs 5.8 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
11.73 vs 8.52 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
11.84 vs 10.26 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
4.54 vs 7.56 placebo score @ 6wk0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
18.85 vs 17.84 placebo score @ 24wk
NCT01668797 · Phase 3
18.63 vs 12.55 placebo score @ 52wk
NCT01668797 · Phase 3
15.2 vs 11.41 placebo score @ 24wk
NCT01668797 · Phase 3
15.06 vs 10.31 placebo score @ 52wk
NCT01668797 · Phase 3
13 vs 9.4 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
11.36 vs 7.56 placebo score @ 6wkLow-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
10.67 vs 7.56 placebo score @ 6wkMid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
12.17 vs 7.56 placebo score @ 6wkHigh-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
PANSS Positive -1.43 vs -1.25 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 35 more results
-2.76 vs -2.56 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-3.56 vs -3.34 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-4.35 vs -3.93 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-4.68 vs -4.33 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-5.42 vs -4.95 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-1.31 vs -1.09 placebo score @ 1wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.31 vs -2.25 placebo score @ 2wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.21 vs -2.57 placebo score @ 3wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.69 vs -2.9 placebo score @ 4wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-4.05 vs -3.26 placebo score @ 5wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-4.32 vs -3.69 placebo score @ 6wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.8 vs -1.25 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-2.93 vs -2.56 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-4.43 vs -3.34 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-5.16 vs -3.93 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-6.04 vs -4.33 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-6.65 vs -4.95 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-0.7 vs -1.09 placebo score @ 1wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.61 vs -2.25 placebo score @ 2wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.71 vs -2.57 placebo score @ 3wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.09 vs -2.9 placebo score @ 4wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.89 vs -3.26 placebo score @ 5wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.15 vs -3.69 placebo score @ 6wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-0.93 vs -1.25 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-2.54 vs -2.56 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-3.94 vs -3.34 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-4.83 vs -3.93 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-4.8 vs -4.33 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-5.63 vs -4.95 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-0.96 vs -1.09 placebo score @ 1wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.72 vs -2.25 placebo score @ 2wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.07 vs -2.57 placebo score @ 3wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.39 vs -2.9 placebo score @ 4wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.19 vs -3.26 placebo score @ 5wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.22 vs -3.69 placebo score @ 6wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
PANSS Negative -0.52 vs -0.4 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 35 more results
-1.31 vs -0.79 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-1.8 vs -1.18 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.09 vs -1.67 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-2.5 vs -1.74 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-2.91 vs -2.14 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-0.83 vs -0.59 placebo score @ 1wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.46 vs -0.72 placebo score @ 2wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.41 vs -1.14 placebo score @ 3wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.9 vs -0.81 placebo score @ 4wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.24 vs -0.85 placebo score @ 5wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.48 vs -1.2 placebo score @ 6wk2 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-0.88 vs -0.4 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.42 vs -0.79 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.15 vs -1.18 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.69 vs -1.67 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-2.82 vs -1.74 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.36 vs -2.14 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-0.71 vs -0.59 placebo score @ 1wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.76 vs -0.72 placebo score @ 2wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.27 vs -1.14 placebo score @ 3wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.94 vs -0.81 placebo score @ 4wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.19 vs -0.85 placebo score @ 5wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-3.24 vs -1.2 placebo score @ 6wk4 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-0.31 vs -0.4 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.27 vs -0.79 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.06 vs -1.18 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-2.56 vs -1.67 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-2.71 vs -1.74 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-2.92 vs -2.14 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-0.54 vs -0.59 placebo score @ 1wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.08 vs -0.72 placebo score @ 2wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-1.64 vs -1.14 placebo score @ 3wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.36 vs -0.81 placebo score @ 4wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.31 vs -0.85 placebo score @ 5wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
-2.34 vs -1.2 placebo score @ 6wk1 mg
NCT01451164 · Phase 2/3 · registry result, not featured evidence
PANSS 38.5% (n=179) vs 31.7% (n=180) placebo @ 6wk2 mg
responder rate · % of participants
NCT01393613 · Phase 3
show 8 more results
49.7% (n=181) vs 31.7% (n=180) placebo @ 6wk4 mg
NCT01393613 · Phase 3
43.6% (n=117) vs 31.7% (n=180) placebo @ 6wk1 mg
NCT01393613 · Phase 3
40.5% (n=42) vs 49.5% (n=95) placebo @ 6wk0.25 mg
NCT00905307 · Phase 2 · registry result, not featured evidence
43.64% (n=110) vs 28.16% (n=103) placebo @ 6wk
NCT03198078 · Phase 3
48.7% (n=150) vs 32.1% (n=159) placebo @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
57.3% (n=89) vs 49.5% (n=95) placebo @ 6wkLow-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
46.7% (n=90) vs 49.5% (n=95) placebo @ 6wkMid-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
51.6% (n=93) vs 49.5% (n=95) placebo @ 6wkHigh-dose
NCT00905307 · Phase 2 · registry result, not featured evidence
PANSS-EC -0.46 vs -0.48 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-1.31 vs -0.62 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-1.31 vs -0.82 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-1.52 vs -1.12 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-1.48 vs -0.97 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-1.9 vs -1.47 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-2.87 vs -1.64 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.01 vs -0.48 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.21 vs -0.62 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-1.81 vs -0.82 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.12 vs -1.12 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-2.27 vs -0.97 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-2.86 vs -1.47 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-2.75 vs -1.64 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-0.35 vs -0.48 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-0.76 vs -0.62 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-1.21 vs -0.82 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-1.58 vs -1.12 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-1.16 vs -0.97 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-1.94 vs -1.47 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-1.99 vs -1.64 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.32 vs 0.74 placebo score @ 6wk
NCT01668797 · Phase 3
0.5 vs 1.16 placebo score @ 12wk
NCT01668797 · Phase 3
-0.06 vs 0.45 placebo score @ 24wk
NCT01668797 · Phase 3
0.1 vs 1.25 placebo score @ 36wk
NCT01668797 · Phase 3
-0.04 vs 1 placebo score @ 52wk
NCT01668797 · Phase 3
0.38 vs 0.81 placebo score @ 6wk
NCT01668797 · Phase 3
0.73 vs 1.36 placebo score @ 12wk
NCT01668797 · Phase 3
0.78 vs 1.86 placebo score @ 24wk
NCT01668797 · Phase 3
0.89 vs 2.23 placebo score @ 36wk
NCT01668797 · Phase 3
0.82 vs 2.35 placebo score @ 52wk
NCT01668797 · Phase 3
-3.3 vs -2.5 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -1.77 vs -1.3 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-3.1 vs -3.03 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-4.09 vs -3.78 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-4.93 vs -4.67 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-5.35 vs -5.47 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-6.26 vs -5.91 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-7.37 vs -4.89 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.75 vs -1.3 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-3.03 vs -3.03 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-4.39 vs -3.78 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-5.48 vs -4.67 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-6.41 vs -5.47 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-7.05 vs -5.91 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-7.23 vs -4.89 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-1.44 vs -1.3 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-2.97 vs -3.03 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-4.48 vs -3.78 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-5.42 vs -4.67 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-5.86 vs -5.47 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-6.56 vs -5.91 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-5.78 vs -4.89 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
-0.1 vs 1.24 placebo score @ 6wk
NCT01668797 · Phase 3
-0.18 vs 1.83 placebo score @ 12wk
NCT01668797 · Phase 3
-0.82 vs 0.77 placebo score @ 24wk
NCT01668797 · Phase 3
-1.35 vs 0.93 placebo score @ 36wk
NCT01668797 · Phase 3
-1.62 vs 1.78 placebo score @ 52wk
NCT01668797 · Phase 3
0.05 vs 1.13 placebo score @ 6wk
NCT01668797 · Phase 3
0.1 vs 2.03 placebo score @ 12wk
NCT01668797 · Phase 3
0.25 vs 3.08 placebo score @ 24wk
NCT01668797 · Phase 3
0.6 vs 3.69 placebo score @ 36wk
NCT01668797 · Phase 3
0.58 vs 4.02 placebo score @ 52wk
NCT01668797 · Phase 3
-7.1 vs -5.7 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative -0.85 vs -0.66 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-1.86 vs -1.38 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-2.3 vs -1.83 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.63 vs -2.16 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-3.13 vs -2.24 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-3.53 vs -2.55 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-4.48 vs -2.8 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.12 vs -0.66 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.72 vs -1.38 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.64 vs -1.83 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-3.17 vs -2.16 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-3.21 vs -2.24 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.84 vs -2.55 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-4.1 vs -2.8 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-0.7 vs -0.66 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.71 vs -1.38 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.55 vs -1.83 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-3.21 vs -2.16 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-3.35 vs -2.24 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-3.55 vs -2.55 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-3.66 vs -2.8 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.02 vs 0.68 placebo score @ 6wk
NCT01668797 · Phase 3
-0.01 vs 0.8 placebo score @ 12wk
NCT01668797 · Phase 3
-0.71 vs 0.46 placebo score @ 24wk
NCT01668797 · Phase 3
-0.8 vs 0.7 placebo score @ 36wk
NCT01668797 · Phase 3
1.37 vs 1.06 placebo score @ 52wk
NCT01668797 · Phase 3
-0.24 vs 0.61 placebo score @ 6wk
NCT01668797 · Phase 3
-0.15 vs 1.09 placebo score @ 12wk
NCT01668797 · Phase 3
-0.09 vs 1.5 placebo score @ 24wk
NCT01668797 · Phase 3
-0.07 vs 1.56 placebo score @ 36wk
NCT01668797 · Phase 3
0.34 vs 1.57 placebo score @ 52wk
NCT01668797 · Phase 3
-4.3 vs -3.6 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganized Thought -0.46 vs -0.42 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 28 more results
-1.15 vs -0.71 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-1.71 vs -1.35 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.27 vs -1.77 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-2.55 vs -2.01 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-2.94 vs -2.59 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-0.78 vs -0.42 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.37 vs -0.71 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.32 vs -1.35 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.83 vs -1.77 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-3.42 vs -2.01 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.98 vs -2.59 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-0.4 vs -0.42 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.42 vs -0.71 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.35 vs -1.35 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-2.56 vs -1.77 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-2.95 vs -2.01 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-3.46 vs -2.59 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-0.18 vs 0.32 placebo score @ 6wk
NCT01668797 · Phase 3
-0.44 vs 0.69 placebo score @ 12wk
NCT01668797 · Phase 3
-1.26 vs 0.27 placebo score @ 24wk
NCT01668797 · Phase 3
-1.31 vs 0.17 placebo score @ 36wk
NCT01668797 · Phase 3
-0.37 vs -0.3 placebo score @ 52wk
NCT01668797 · Phase 3
-0.32 vs 0.33 placebo score @ 6wk
NCT01668797 · Phase 3
-0.19 vs 1.19 placebo score @ 12wk
NCT01668797 · Phase 3
-0.29 vs 1.76 placebo score @ 24wk
NCT01668797 · Phase 3
0 vs 1.95 placebo score @ 36wk
NCT01668797 · Phase 3
0.29 vs 1.97 placebo score @ 52wk
NCT01668797 · Phase 3
-4 vs -3.2 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.1 vs -0.21 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-0.65 vs -0.13 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-0.61 vs -0.19 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-0.74 vs -0.39 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-0.6 vs -0.22 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-0.81 vs -0.64 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-1.91 vs -0.82 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-0.63 vs -0.21 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-0.68 vs -0.13 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-1.16 vs -0.19 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-1.31 vs -0.39 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-1.5 vs -0.22 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-1.89 vs -0.64 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-1.9 vs -0.82 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
0.03 vs -0.21 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-0.15 vs -0.13 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-0.46 vs -0.19 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-0.74 vs -0.39 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-0.34 vs -0.22 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-0.9 vs -0.64 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-1.15 vs -0.82 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.19 vs 0.55 placebo score @ 6wk
NCT01668797 · Phase 3
0.33 vs 0.82 placebo score @ 12wk
NCT01668797 · Phase 3
-0.26 vs 0.81 placebo score @ 24wk
NCT01668797 · Phase 3
-0.13 vs 0.94 placebo score @ 36wk
NCT01668797 · Phase 3
-0.2 vs 0.94 placebo score @ 52wk
NCT01668797 · Phase 3
0.32 vs 0.65 placebo score @ 6wk
NCT01668797 · Phase 3
0.52 vs 0.94 placebo score @ 12wk
NCT01668797 · Phase 3
0.5 vs 1.31 placebo score @ 24wk
NCT01668797 · Phase 3
0.57 vs 1.63 placebo score @ 36wk
NCT01668797 · Phase 3
0.49 vs 1.75 placebo score @ 52wk
NCT01668797 · Phase 3
-2.5 vs -1.8 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Anxiety Depression -1.1 vs -0.96 placebo score @ 1wk2 mg
absolute change · score
NCT01393613 · Phase 3
show 31 more results
-1.91 vs -1.47 placebo score @ 2wk2 mg
NCT01393613 · Phase 3
-2.1 vs -1.97 placebo score @ 3wk2 mg
NCT01393613 · Phase 3
-2.7 vs -2.6 placebo score @ 4wk2 mg
NCT01393613 · Phase 3
-2.87 vs -2.69 placebo score @ 5wk2 mg
NCT01393613 · Phase 3
-3.62 vs -2.93 placebo score @ 6wk2 mg
NCT01393613 · Phase 3
-3.7 vs -3.05 placebo score @ 6wk2 mg
NCT01396421 · Phase 3
-1.26 vs -0.96 placebo score @ 1wk4 mg
NCT01393613 · Phase 3
-1.6 vs -1.47 placebo score @ 2wk4 mg
NCT01393613 · Phase 3
-2.24 vs -1.97 placebo score @ 3wk4 mg
NCT01393613 · Phase 3
-2.93 vs -2.6 placebo score @ 4wk4 mg
NCT01393613 · Phase 3
-3.09 vs -2.69 placebo score @ 5wk4 mg
NCT01393613 · Phase 3
-3.78 vs -2.93 placebo score @ 6wk4 mg
NCT01393613 · Phase 3
-3.4 vs -3.05 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-1.18 vs -0.96 placebo score @ 1wk1 mg
NCT01393613 · Phase 3
-1.86 vs -1.47 placebo score @ 2wk1 mg
NCT01393613 · Phase 3
-2.43 vs -1.97 placebo score @ 3wk1 mg
NCT01393613 · Phase 3
-2.85 vs -2.6 placebo score @ 4wk1 mg
NCT01393613 · Phase 3
-2.93 vs -2.69 placebo score @ 5wk1 mg
NCT01393613 · Phase 3
-3.57 vs -2.93 placebo score @ 6wk1 mg
NCT01393613 · Phase 3
-3.27 vs -3.05 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
0.19 vs 0.66 placebo score @ 6wk
NCT01668797 · Phase 3
0.54 vs 0.78 placebo score @ 12wk
NCT01668797 · Phase 3
0.61 vs 0.58 placebo score @ 24wk
NCT01668797 · Phase 3
0.46 vs 0.71 placebo score @ 36wk
NCT01668797 · Phase 3
0.04 vs 0.28 placebo score @ 52wk
NCT01668797 · Phase 3
0.19 vs 0.85 placebo score @ 6wk
NCT01668797 · Phase 3
0.86 vs 1.41 placebo score @ 12wk
NCT01668797 · Phase 3
1.07 vs 1.64 placebo score @ 24wk
NCT01668797 · Phase 3
1.09 vs 1.79 placebo score @ 36wk
NCT01668797 · Phase 3
1.17 vs 1.88 placebo score @ 52wk
NCT01668797 · Phase 3
-3.2 vs -2.9 placebo score @ 6wk
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Disorganised Thought -3.94 vs -1.97 placebo score @ 6wk2 mg
absolute change · score
NCT01396421 · Phase 3
show 2 more results
-3.72 vs -1.97 placebo score @ 6wk4 mg
NCT01396421 · Phase 3
-2.69 vs -1.97 placebo score @ 6wk0.25 mg
NCT01396421 · Phase 3
CGI-S -1.09 score
absolute value · score
No placebo or comparator arm
NCT03238326 · Phase 3
show 3 more results
-1.11 score
NCT03238326 · Phase 3
-0.86 score
NCT03238326 · Phase 3
-1.3 score
NCT03238326 · Phase 3

+ 36 further endpoints in the CSV export.

Major Depressive Disorder

Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Major Depressive Disorder pipeline

Aripiprazole (Abilify)

Marketed by Otsuka Holdings and partners

Approved in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07011693 (registry estimate)

No aligned efficacy figure on record for this race.

Brexpiprazole (Rexulti)

Marketed by Otsuka Holdings and partners

Approved in Major Depressive Disordersmall molecule
Partial signal

NCT01360632 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled Phase 3 trial with 677 randomized participants and a clinical primary endpoint (MADRS change). The 3 mg brexpiprazole arm met the primary endpoint versus placebo (p=0.0327), while the 1 mg arm missed (p=0.0925). Because the primary result was not consistent across the two active doses, the evidence is considered moderate rather than strong.

Next expected readout: December 2028 · NCT05017311 (registry estimate)

Reported efficacy

Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14); Change From Baseline (End of Phase A [Week 8]) to Week 14 in MADRS Total Score for the Efficacy Sample Per the Final Protocol. (Baseline and Week 14): Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14): Brexpiprazole 2 mg/Day + ADT -8.27 Units on a scale (Standard Error 0.61) vs Double-blind Placebo + ADT -5.15 Units on a scale (Standard Error 0.6) (met)

Result source: NCT01360645

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAripiprazole (Abilify)Brexpiprazole (Rexulti)
MADRS, change (acute)—Not posted · NCT00095823-8.3 vs -5.2−3.1 vs placebo2 mg/Day · wk 14 · n 187NCT01360645
68 other results
  • -8.4 vs -5.2 2 mg/Day · wk 14 · n 175 · Phase 3 · primary NCT01360645
  • -8.2 vs -6.7 2 mg · wk 6 · n 245 · Phase 2/3 · primary NCT03697603
  • -7.7 vs -6.5 1 mg · wk 14 · n 225 · Phase 3 · primary NCT01360632
  • -7.6 vs 6.3 1 mg · wk 14 · n 211 · Phase 3 · primary NCT01360632
  • -8.5 vs -6.7 1 mg · wk 6 · n 248 · Phase 2/3 · primary NCT03697603
  • -8.0 vs -6.5 3 mg · wk 14 · n 226 · Phase 3 · primary NCT01360632
  • -8.3 vs 6.3 3 mg · wk 14 · n 213 · Phase 3 · primary NCT01360632
  • -10.4 vs -8.1 wk 14 · n 191 · Phase 3 · primary NCT02196506
  • -8.3 vs -5.1 2 mg/Day · wk 13 · n 187 · Phase 3 · secondary NCT01360645
  • -8.3 vs -5.0 2 mg/Day · wk 13 · n 175 · Phase 3 · secondary NCT01360645
  • -7.2 vs -4.6 2 mg/Day · wk 12 · n 187 · Phase 3 · secondary NCT01360645
  • -7.2 vs -4.7 2 mg/Day · wk 12 · n 175 · Phase 3 · secondary NCT01360645
  • -6.7 vs -4.1 2 mg/Day · wk 11 · n 187 · Phase 3 · secondary NCT01360645
  • -6.6 vs -4.2 2 mg/Day · wk 11 · n 175 · Phase 3 · secondary NCT01360645
  • -5.2 vs -3.4 2 mg/Day · wk 10 · n 187 · Phase 3 · secondary NCT01360645
  • -5.0 vs -3.5 2 mg/Day · wk 10 · n 175 · Phase 3 · secondary NCT01360645
  • -3.1 vs -1.9 2 mg/Day · wk 9 · n 187 · Phase 3 · secondary NCT01360645
  • -3.0 vs -1.7 2 mg/Day · wk 9 · n 175 · Phase 3 · secondary NCT01360645
  • -7.5 vs -6.0 1 mg · wk 13 · n 225 · Phase 3 · secondary NCT01360632
  • -7.6 vs -5.9 1 mg · wk 13 · n 211 · Phase 3 · secondary NCT01360632
  • -7.1 vs -5.5 1 mg · wk 12 · n 225 · Phase 3 · secondary NCT01360632
  • -7.1 vs -5.5 1 mg · wk 12 · n 211 · Phase 3 · secondary NCT01360632
  • -6.3 vs -4.8 1 mg · wk 11 · n 225 · Phase 3 · secondary NCT01360632
  • -6.2 vs -4.9 1 mg · wk 11 · n 211 · Phase 3 · secondary NCT01360632
  • -5.3 vs -3.9 1 mg · wk 10 · n 225 · Phase 3 · secondary NCT01360632
  • -5.1 vs -4.0 1 mg · wk 10 · n 211 · Phase 3 · secondary NCT01360632
  • -3.3 vs -2.2 1 mg · wk 9 · n 225 · Phase 3 · secondary NCT01360632
  • -3.1 vs -2.2 1 mg · wk 9 · n 211 · Phase 3 · secondary NCT01360632
  • -7.7 vs -6.0 3 mg · wk 13 · n 226 · Phase 3 · secondary NCT01360632
  • -8.1 vs -5.9 3 mg · wk 13 · n 213 · Phase 3 · secondary NCT01360632
  • -6.8 vs -5.5 3 mg · wk 12 · n 226 · Phase 3 · secondary NCT01360632
  • -7.1 vs -5.5 3 mg · wk 12 · n 213 · Phase 3 · secondary NCT01360632
  • -5.6 vs -4.8 3 mg · wk 11 · n 226 · Phase 3 · secondary NCT01360632
  • -5.8 vs -4.9 3 mg · wk 11 · n 213 · Phase 3 · secondary NCT01360632
  • -4.8 vs -3.9 3 mg · wk 10 · n 226 · Phase 3 · secondary NCT01360632
  • -4.9 vs -4.0 3 mg · wk 10 · n 213 · Phase 3 · secondary NCT01360632
  • -2.5 vs -2.2 3 mg · wk 9 · n 226 · Phase 3 · secondary NCT01360632
  • -2.6 vs -2.2 3 mg · wk 9 · n 213 · Phase 3 · secondary NCT01360632
  • -11.1 vs -8.9 wk 14 · n 161 · Phase 3 · secondary NCT02196506
  • -6.3 vs -5.9 wk 6 · n 422 · Phase 3 · secondary NCT01838681
  • -11.8 vs -8.9 wk 14 · n 124 · Phase 3 · secondary NCT02196506
  • -4.4 vs -3.2 wk 4 · n 191 · Phase 3 · secondary NCT01727726
  • -2.6 vs -1.0 wk 2 · n 191 · Phase 3 · secondary NCT01727726
  • -8.2 vs -6.1 1.5 ± 0.5 mg high dose · wk 14 · n 118 · Phase 2 · primary NCT00797966
  • -6.5 vs -6.1 0.5 ± 0.25 mg low dose · wk 14 · n 119 · Phase 2 · primary NCT00797966
  • -6.6 vs -6.1 0.15 mg fixed dose · wk 14 · n 62 · Phase 2 · primary NCT00797966
  • -8.2 vs -7.0 wk 14 · n 184 · Phase 2 · primary NCT01052077
  • -7.2 vs -5.5 1.5 ± 0.5 mg high dose · wk 13 · n 118 · Phase 2 · secondary NCT00797966
  • -7.0 vs -4.4 1.5 ± 0.5 mg high dose · wk 12 · n 118 · Phase 2 · secondary NCT00797966
  • -5.9 vs -4.4 1.5 ± 0.5 mg high dose · wk 11 · n 118 · Phase 2 · secondary NCT00797966
  • -5.0 vs -3.6 1.5 ± 0.5 mg high dose · wk 10 · n 118 · Phase 2 · secondary NCT00797966
  • -2.8 vs -2.5 1.5 ± 0.5 mg high dose · wk 9 · n 118 · Phase 2 · secondary NCT00797966
  • -6.8 vs -5.5 0.5 ± 0.25 mg low dose · wk 13 · n 119 · Phase 2 · secondary NCT00797966
  • -6.3 vs -4.4 0.5 ± 0.25 mg low dose · wk 12 · n 119 · Phase 2 · secondary NCT00797966
  • -5.7 vs -4.4 0.5 ± 0.25 mg low dose · wk 11 · n 119 · Phase 2 · secondary NCT00797966
  • -3.8 vs -3.6 0.5 ± 0.25 mg low dose · wk 10 · n 119 · Phase 2 · secondary NCT00797966
  • -3 vs -2.5 0.5 ± 0.25 mg low dose · wk 9 · n 119 · Phase 2 · secondary NCT00797966
  • -6.9 vs -5.5 0.15 mg fixed dose · wk 13 · n 62 · Phase 2 · secondary NCT00797966
  • -7.0 vs -4.4 0.15 mg fixed dose · wk 12 · n 62 · Phase 2 · secondary NCT00797966
  • -5.5 vs -4.4 0.15 mg fixed dose · wk 11 · n 62 · Phase 2 · secondary NCT00797966
  • -3.7 vs -3.6 0.15 mg fixed dose · wk 10 · n 62 · Phase 2 · secondary NCT00797966
  • -2.1 vs -2.5 0.15 mg fixed dose · wk 9 · n 62 · Phase 2 · secondary NCT00797966
  • -8.2 vs -7.0 wk 14 · n 184 · Phase 2 · secondary NCT01052077
  • -9 vs -7.2 wk 13 · n 184 · Phase 2 · secondary NCT01052077
  • -8.4 vs -6.2 wk 12 · n 184 · Phase 2 · secondary NCT01052077
  • -7.2 vs -5.2 wk 11 · n 184 · Phase 2 · secondary NCT01052077
  • -5.9 vs -4.0 wk 10 · n 184 · Phase 2 · secondary NCT01052077
  • -3.3 vs -2.0 wk 9 · n 184 · Phase 2 · secondary NCT01052077
CGI-S, change (acute)—Not posted · NCT00095823-0.9 vs -0.6−0.3 vs placebo2 mg/Day · wk 14 · n 187NCT01360645
60 other results
  • -0.9 vs -0.6 2 mg/Day · wk 14 · n 175 · Phase 3 · secondary NCT01360645
  • -0.9 vs -0.5 2 mg/Day · wk 13 · n 187 · Phase 3 · secondary NCT01360645
  • -0.8 vs -0.5 2 mg/Day · wk 13 · n 175 · Phase 3 · secondary NCT01360645
  • -0.7 vs -0.5 2 mg/Day · wk 12 · n 187 · Phase 3 · secondary NCT01360645
  • -0.7 vs -0.5 2 mg/Day · wk 12 · n 175 · Phase 3 · secondary NCT01360645
  • -0.6 vs -0.4 2 mg/Day · wk 11 · n 187 · Phase 3 · secondary NCT01360645
  • -0.6 vs -0.4 2 mg/Day · wk 11 · n 175 · Phase 3 · secondary NCT01360645
  • -0.5 vs -0.3 2 mg/Day · wk 10 · n 187 · Phase 3 · secondary NCT01360645
  • -0.4 vs -0.3 2 mg/Day · wk 10 · n 175 · Phase 3 · secondary NCT01360645
  • -0.3 vs -0.1 2 mg/Day · wk 9 · n 187 · Phase 3 · secondary NCT01360645
  • -0.2 vs -0.1 2 mg/Day · wk 9 · n 175 · Phase 3 · secondary NCT01360645
  • -0.9 vs -0.8 1 mg · wk 14 · n 225 · Phase 3 · secondary NCT01360632
  • -0.9 vs -0.7 1 mg · wk 14 · n 211 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.7 1 mg · wk 13 · n 225 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.6 1 mg · wk 13 · n 211 · Phase 3 · secondary NCT01360632
  • -0.7 vs -0.6 1 mg · wk 12 · n 225 · Phase 3 · secondary NCT01360632
  • -0.7 vs -0.6 1 mg · wk 12 · n 211 · Phase 3 · secondary NCT01360632
  • -0.6 vs -0.4 1 mg · wk 11 · n 225 · Phase 3 · secondary NCT01360632
  • -0.6 vs -0.5 1 mg · wk 11 · n 211 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.3 1 mg · wk 10 · n 225 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.3 1 mg · wk 10 · n 211 · Phase 3 · secondary NCT01360632
  • -0.3 vs -0.2 1 mg · wk 9 · n 225 · Phase 3 · secondary NCT01360632
  • -0.2 vs -0.2 1 mg · wk 9 · n 211 · Phase 3 · secondary NCT01360632
  • -0.9 vs -0.8 3 mg · wk 14 · n 226 · Phase 3 · secondary NCT01360632
  • -0.9 vs -0.7 3 mg · wk 14 · n 213 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.7 3 mg · wk 13 · n 226 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.6 3 mg · wk 13 · n 213 · Phase 3 · secondary NCT01360632
  • -0.7 vs -0.6 3 mg · wk 12 · n 226 · Phase 3 · secondary NCT01360632
  • -0.7 vs -0.6 3 mg · wk 12 · n 213 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.4 3 mg · wk 11 · n 226 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.5 3 mg · wk 11 · n 213 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.3 3 mg · wk 10 · n 226 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.3 3 mg · wk 10 · n 213 · Phase 3 · secondary NCT01360632
  • -0.2 vs -0.2 3 mg · wk 9 · n 226 · Phase 3 · secondary NCT01360632
  • -0.2 vs -0.2 3 mg · wk 9 · n 213 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.8 wk 6 · n 422 · Phase 3 · secondary NCT01838681
  • -1.1 vs -0.7 1.5 ± 0.5 mg high dose · wk 14 · n 118 · Phase 2 · secondary NCT00797966
  • -0.9 vs -0.6 1.5 ± 0.5 mg high dose · wk 13 · n 118 · Phase 2 · secondary NCT00797966
  • -0.9 vs -0.5 1.5 ± 0.5 mg high dose · wk 12 · n 118 · Phase 2 · secondary NCT00797966
  • -0.7 vs -0.5 1.5 ± 0.5 mg high dose · wk 11 · n 118 · Phase 2 · secondary NCT00797966
  • -0.6 vs -0.4 1.5 ± 0.5 mg high dose · wk 10 · n 118 · Phase 2 · secondary NCT00797966
  • -0.3 vs -0.2 1.5 ± 0.5 mg high dose · wk 9 · n 118 · Phase 2 · secondary NCT00797966
  • -0.8 vs -0.7 0.5 ± 0.25 mg low dose · wk 14 · n 119 · Phase 2 · secondary NCT00797966
  • -0.8 vs -0.6 0.5 ± 0.25 mg low dose · wk 13 · n 119 · Phase 2 · secondary NCT00797966
  • -0.7 vs -0.5 0.5 ± 0.25 mg low dose · wk 12 · n 119 · Phase 2 · secondary NCT00797966
  • -0.5 vs -0.5 0.5 ± 0.25 mg low dose · wk 11 · n 119 · Phase 2 · secondary NCT00797966
  • -0.4 vs -0.4 0.5 ± 0.25 mg low dose · wk 10 · n 119 · Phase 2 · secondary NCT00797966
  • -0.3 vs -0.2 0.5 ± 0.25 mg low dose · wk 9 · n 119 · Phase 2 · secondary NCT00797966
  • -0.8 vs -0.7 0.15 mg fixed dose · wk 14 · n 62 · Phase 2 · secondary NCT00797966
  • -0.7 vs -0.6 0.15 mg fixed dose · wk 13 · n 62 · Phase 2 · secondary NCT00797966
  • -0.8 vs -0.5 0.15 mg fixed dose · wk 12 · n 62 · Phase 2 · secondary NCT00797966
  • -0.5 vs -0.5 0.15 mg fixed dose · wk 11 · n 62 · Phase 2 · secondary NCT00797966
  • -0.4 vs -0.4 0.15 mg fixed dose · wk 10 · n 62 · Phase 2 · secondary NCT00797966
  • -0.2 vs -0.2 0.15 mg fixed dose · wk 9 · n 62 · Phase 2 · secondary NCT00797966
  • -0.9 vs -0.8 wk 14 · n 184 · Phase 2 · secondary NCT01052077
  • -1 vs -0.8 wk 13 · n 184 · Phase 2 · secondary NCT01052077
  • -0.9 vs -0.7 wk 12 · n 184 · Phase 2 · secondary NCT01052077
  • -0.8 vs -0.6 wk 11 · n 184 · Phase 2 · secondary NCT01052077
  • -0.6 vs -0.4 wk 10 · n 184 · Phase 2 · secondary NCT01052077
  • -0.3 vs -0.2 wk 9 · n 184 · Phase 2 · secondary NCT01052077
MADRS response—Not posted · NCT0009582323.5% vs 14.7%+8.8 vs placebo2 mg/Day · wk 14 · n 187NCT01360645
51 other results
  • 23.4% vs 15.7% 2 mg/Day · wk 14 · n 175 · Phase 3 · secondary NCT01360645
  • 23.1% vs 15.1% 1 mg · wk 14 · n 225 · Phase 3 · secondary NCT01360632
  • 23.2% vs 14.3% 1 mg · wk 14 · n 211 · Phase 3 · secondary NCT01360632
  • 18.2% vs 15.6% 1 mg · wk 13 · n 225 · Phase 3 · secondary NCT01360632
  • 18% vs 14.3% 1 mg · wk 13 · n 211 · Phase 3 · secondary NCT01360632
  • 16.9% vs 10.1% 1 mg · wk 12 · n 225 · Phase 3 · secondary NCT01360632
  • 16.6% vs 10.3% 1 mg · wk 12 · n 211 · Phase 3 · secondary NCT01360632
  • 13.3% vs 8.7% 1 mg · wk 11 · n 225 · Phase 3 · secondary NCT01360632
  • 13.3% vs 8.4% 1 mg · wk 11 · n 211 · Phase 3 · secondary NCT01360632
  • 10.2% vs 5.0% 1 mg · wk 10 · n 225 · Phase 3 · secondary NCT01360632
  • 7.6% vs 4.9% 1 mg · wk 10 · n 211 · Phase 3 · secondary NCT01360632
  • 4.5% vs 2.8% 1 mg · wk 9 · n 225 · Phase 3 · secondary NCT01360632
  • 3.4% vs 3.0% 1 mg · wk 9 · n 211 · Phase 3 · secondary NCT01360632
  • 22.1% vs 15.1% 3 mg · wk 14 · n 226 · Phase 3 · secondary NCT01360632
  • 23% vs 14.3% 3 mg · wk 14 · n 213 · Phase 3 · secondary NCT01360632
  • 18.6% vs 15.6% 3 mg · wk 13 · n 226 · Phase 3 · secondary NCT01360632
  • 19.2% vs 14.3% 3 mg · wk 13 · n 213 · Phase 3 · secondary NCT01360632
  • 15.5% vs 10.1% 3 mg · wk 12 · n 226 · Phase 3 · secondary NCT01360632
  • 16.4% vs 10.3% 3 mg · wk 12 · n 213 · Phase 3 · secondary NCT01360632
  • 10.6% vs 8.7% 3 mg · wk 11 · n 226 · Phase 3 · secondary NCT01360632
  • 11.3% vs 8.4% 3 mg · wk 11 · n 213 · Phase 3 · secondary NCT01360632
  • 6.2% vs 5.0% 3 mg · wk 10 · n 226 · Phase 3 · secondary NCT01360632
  • 6.1% vs 4.9% 3 mg · wk 10 · n 213 · Phase 3 · secondary NCT01360632
  • 0.5% vs 2.8% 3 mg · wk 9 · n 226 · Phase 3 · secondary NCT01360632
  • 0.5% vs 3.0% 3 mg · wk 9 · n 213 · Phase 3 · secondary NCT01360632
  • 10.5% vs 6.8% wk 6 · n 191 · Phase 3 · secondary NCT01727726
  • 18.6% vs 17.3% wk 6 · n 442 · Phase 3 · secondary NCT01838681
  • 34.7% vs 19.8% 1.5 ± 0.5 mg high dose · wk 14 · n 118 · Phase 2 · secondary NCT00797966
  • 25.4% vs 18.3% 1.5 ± 0.5 mg high dose · wk 13 · n 118 · Phase 2 · secondary NCT00797966
  • 25.4% vs 11.9% 1.5 ± 0.5 mg high dose · wk 12 · n 118 · Phase 2 · secondary NCT00797966
  • 18.6% vs 13.5% 1.5 ± 0.5 mg high dose · wk 11 · n 118 · Phase 2 · secondary NCT00797966
  • 11% vs 9.5% 1.5 ± 0.5 mg high dose · wk 10 · n 118 · Phase 2 · secondary NCT00797966
  • 2.6% vs 8.3% 1.5 ± 0.5 mg high dose · wk 9 · n 118 · Phase 2 · secondary NCT00797966
  • 20.2% vs 19.8% 0.5 ± 0.25 mg low dose · wk 14 · n 119 · Phase 2 · secondary NCT00797966
  • 22.7% vs 18.3% 0.5 ± 0.25 mg low dose · wk 13 · n 119 · Phase 2 · secondary NCT00797966
  • 15.1% vs 11.9% 0.5 ± 0.25 mg low dose · wk 12 · n 119 · Phase 2 · secondary NCT00797966
  • 15.1% vs 13.5% 0.5 ± 0.25 mg low dose · wk 11 · n 119 · Phase 2 · secondary NCT00797966
  • 8.4% vs 9.5% 0.5 ± 0.25 mg low dose · wk 10 · n 119 · Phase 2 · secondary NCT00797966
  • 6.8% vs 8.3% 0.5 ± 0.25 mg low dose · wk 9 · n 119 · Phase 2 · secondary NCT00797966
  • 27.4% vs 19.8% 0.15 mg fixed dose · wk 14 · n 62 · Phase 2 · secondary NCT00797966
  • 24.2% vs 18.3% 0.15 mg fixed dose · wk 13 · n 62 · Phase 2 · secondary NCT00797966
  • 30.6% vs 11.9% 0.15 mg fixed dose · wk 12 · n 62 · Phase 2 · secondary NCT00797966
  • 19.4% vs 13.5% 0.15 mg fixed dose · wk 11 · n 62 · Phase 2 · secondary NCT00797966
  • 8.1% vs 9.5% 0.15 mg fixed dose · wk 10 · n 62 · Phase 2 · secondary NCT00797966
  • 4.9% vs 8.3% 0.15 mg fixed dose · wk 9 · n 62 · Phase 2 · secondary NCT00797966
  • 29.9% vs 19.9% wk 14 · n 184 · Phase 2 · secondary NCT01052077
  • 29.9% vs 18.2% wk 13 · n 184 · Phase 2 · secondary NCT01052077
  • 30.4% vs 15.5% wk 12 · n 184 · Phase 2 · secondary NCT01052077
  • 22.3% vs 14.4% wk 11 · n 184 · Phase 2 · secondary NCT01052077
  • 15.8% vs 8.8% wk 10 · n 184 · Phase 2 · secondary NCT01052077
  • 6% vs 2.2% wk 9 · n 184 · Phase 2 · secondary NCT01052077
MADRS remission—Not posted · NCT0009582314.4% vs 8.4%+6 vs placebo2 mg/Day · wk 14 · n 187NCT01360645
50 other results
  • 14.9% vs 9.0% 2 mg/Day · wk 14 · n 175 · Phase 3 · secondary NCT01360645
  • 15.1% vs 11.9% 1 mg · wk 14 · n 222 · Phase 3 · secondary NCT01360632
  • 14.7% vs 10.8% 1 mg · wk 14 · n 211 · Phase 3 · secondary NCT01360632
  • 10.7% vs 9.2% 1 mg · wk 13 · n 222 · Phase 3 · secondary NCT01360632
  • 9.9% vs 8.4% 1 mg · wk 13 · n 211 · Phase 3 · secondary NCT01360632
  • 11.1% vs 6.0% 1 mg · wk 12 · n 222 · Phase 3 · secondary NCT01360632
  • 10.4% vs 6.4% 1 mg · wk 12 · n 211 · Phase 3 · secondary NCT01360632
  • 8.4% vs 5.5% 1 mg · wk 11 · n 222 · Phase 3 · secondary NCT01360632
  • 8.1% vs 5.4% 1 mg · wk 11 · n 211 · Phase 3 · secondary NCT01360632
  • 4% vs 4.1% 1 mg · wk 10 · n 222 · Phase 3 · secondary NCT01360632
  • 2.4% vs 3.9% 1 mg · wk 10 · n 211 · Phase 3 · secondary NCT01360632
  • 3.1% vs 2.8% 1 mg · wk 9 · n 222 · Phase 3 · secondary NCT01360632
  • 1.9% vs 3.0% 1 mg · wk 9 · n 211 · Phase 3 · secondary NCT01360632
  • 13.7% vs 11.9% 3 mg · wk 14 · n 221 · Phase 3 · secondary NCT01360632
  • 14.1% vs 10.8% 3 mg · wk 14 · n 213 · Phase 3 · secondary NCT01360632
  • 12.8% vs 9.2% 3 mg · wk 13 · n 221 · Phase 3 · secondary NCT01360632
  • 13.1% vs 8.4% 3 mg · wk 13 · n 213 · Phase 3 · secondary NCT01360632
  • 8.8% vs 6.0% 3 mg · wk 12 · n 221 · Phase 3 · secondary NCT01360632
  • 9.4% vs 6.4% 3 mg · wk 12 · n 213 · Phase 3 · secondary NCT01360632
  • 6.2% vs 5.5% 3 mg · wk 11 · n 221 · Phase 3 · secondary NCT01360632
  • 6.6% vs 5.4% 3 mg · wk 11 · n 213 · Phase 3 · secondary NCT01360632
  • 2.6% vs 4.1% 3 mg · wk 10 · n 221 · Phase 3 · secondary NCT01360632
  • 2.8% vs 3.9% 3 mg · wk 10 · n 213 · Phase 3 · secondary NCT01360632
  • 0.5% vs 2.8% 3 mg · wk 9 · n 221 · Phase 3 · secondary NCT01360632
  • 0.5% vs 3.0% 3 mg · wk 9 · n 213 · Phase 3 · secondary NCT01360632
  • 12% vs 10.5% wk 6 · n 442 · Phase 3 · secondary NCT01838681
  • 23.7% vs 13.5% 1.5 ± 0.5 mg high dose · wk 14 · n 118 · Phase 2 · secondary NCT00797966
  • 15.3% vs 15.1% 1.5 ± 0.5 mg high dose · wk 13 · n 118 · Phase 2 · secondary NCT00797966
  • 19.5% vs 10.3% 1.5 ± 0.5 mg high dose · wk 12 · n 118 · Phase 2 · secondary NCT00797966
  • 14.4% vs 11.1% 1.5 ± 0.5 mg high dose · wk 11 · n 118 · Phase 2 · secondary NCT00797966
  • 10.2% vs 8.7% 1.5 ± 0.5 mg high dose · wk 10 · n 118 · Phase 2 · secondary NCT00797966
  • 1.7% vs 4.1% 1.5 ± 0.5 mg high dose · wk 9 · n 118 · Phase 2 · secondary NCT00797966
  • 15.1% vs 13.5% 0.5 ± 0.25 mg low dose · wk 14 · n 119 · Phase 2 · secondary NCT00797966
  • 16.8% vs 15.1% 0.5 ± 0.25 mg low dose · wk 13 · n 119 · Phase 2 · secondary NCT00797966
  • 10.1% vs 10.3% 0.5 ± 0.25 mg low dose · wk 12 · n 119 · Phase 2 · secondary NCT00797966
  • 10.1% vs 11.1% 0.5 ± 0.25 mg low dose · wk 11 · n 119 · Phase 2 · secondary NCT00797966
  • 5.0% vs 8.7% 0.5 ± 0.25 mg low dose · wk 10 · n 119 · Phase 2 · secondary NCT00797966
  • 1.7% vs 4.1% 0.5 ± 0.25 mg low dose · wk 9 · n 119 · Phase 2 · secondary NCT00797966
  • 22.6% vs 13.5% 0.15 mg fixed dose · wk 14 · n 62 · Phase 2 · secondary NCT00797966
  • 19.4% vs 15.1% 0.15 mg fixed dose · wk 13 · n 62 · Phase 2 · secondary NCT00797966
  • 21% vs 10.3% 0.15 mg fixed dose · wk 12 · n 62 · Phase 2 · secondary NCT00797966
  • 12.9% vs 11.1% 0.15 mg fixed dose · wk 11 · n 62 · Phase 2 · secondary NCT00797966
  • 8.1% vs 8.7% 0.15 mg fixed dose · wk 10 · n 62 · Phase 2 · secondary NCT00797966
  • 3.3% vs 4.1% 0.15 mg fixed dose · wk 9 · n 62 · Phase 2 · secondary NCT00797966
  • 26.1% vs 14.9% wk 14 · n 184 · Phase 2 · secondary NCT01052077
  • 25% vs 13.8% wk 13 · n 184 · Phase 2 · secondary NCT01052077
  • 22.8% vs 10.5% wk 12 · n 184 · Phase 2 · secondary NCT01052077
  • 16.8% vs 9.9% wk 11 · n 184 · Phase 2 · secondary NCT01052077
  • 8.2% vs 3.9% wk 10 · n 184 · Phase 2 · secondary NCT01052077
  • 3.8% vs 1.7% wk 9 · n 184 · Phase 2 · secondary NCT01052077
Relapse (% of patients)—Not posted · NCT0009582322.5% vs 20.6%+1.9 vs placebowk 26 · n 240NCT03538691

MADRS, change (acute)

Aripiprazole (Abilify)
—Not posted · NCT00095823
Brexpiprazole (Rexulti)
-8.3 vs -5.2−3.1 vs placebo2 mg/Day · wk 14 · n 187NCT01360645
68 other results
  • -8.4 vs -5.2 2 mg/Day · wk 14 · n 175 · Phase 3 · primary NCT01360645
  • -8.2 vs -6.7 2 mg · wk 6 · n 245 · Phase 2/3 · primary NCT03697603
  • -7.7 vs -6.5 1 mg · wk 14 · n 225 · Phase 3 · primary NCT01360632
  • -7.6 vs 6.3 1 mg · wk 14 · n 211 · Phase 3 · primary NCT01360632
  • -8.5 vs -6.7 1 mg · wk 6 · n 248 · Phase 2/3 · primary NCT03697603
  • -8.0 vs -6.5 3 mg · wk 14 · n 226 · Phase 3 · primary NCT01360632
  • -8.3 vs 6.3 3 mg · wk 14 · n 213 · Phase 3 · primary NCT01360632
  • -10.4 vs -8.1 wk 14 · n 191 · Phase 3 · primary NCT02196506
  • -8.3 vs -5.1 2 mg/Day · wk 13 · n 187 · Phase 3 · secondary NCT01360645
  • -8.3 vs -5.0 2 mg/Day · wk 13 · n 175 · Phase 3 · secondary NCT01360645
  • -7.2 vs -4.6 2 mg/Day · wk 12 · n 187 · Phase 3 · secondary NCT01360645
  • -7.2 vs -4.7 2 mg/Day · wk 12 · n 175 · Phase 3 · secondary NCT01360645
  • -6.7 vs -4.1 2 mg/Day · wk 11 · n 187 · Phase 3 · secondary NCT01360645
  • -6.6 vs -4.2 2 mg/Day · wk 11 · n 175 · Phase 3 · secondary NCT01360645
  • -5.2 vs -3.4 2 mg/Day · wk 10 · n 187 · Phase 3 · secondary NCT01360645
  • -5.0 vs -3.5 2 mg/Day · wk 10 · n 175 · Phase 3 · secondary NCT01360645
  • -3.1 vs -1.9 2 mg/Day · wk 9 · n 187 · Phase 3 · secondary NCT01360645
  • -3.0 vs -1.7 2 mg/Day · wk 9 · n 175 · Phase 3 · secondary NCT01360645
  • -7.5 vs -6.0 1 mg · wk 13 · n 225 · Phase 3 · secondary NCT01360632
  • -7.6 vs -5.9 1 mg · wk 13 · n 211 · Phase 3 · secondary NCT01360632
  • -7.1 vs -5.5 1 mg · wk 12 · n 225 · Phase 3 · secondary NCT01360632
  • -7.1 vs -5.5 1 mg · wk 12 · n 211 · Phase 3 · secondary NCT01360632
  • -6.3 vs -4.8 1 mg · wk 11 · n 225 · Phase 3 · secondary NCT01360632
  • -6.2 vs -4.9 1 mg · wk 11 · n 211 · Phase 3 · secondary NCT01360632
  • -5.3 vs -3.9 1 mg · wk 10 · n 225 · Phase 3 · secondary NCT01360632
  • -5.1 vs -4.0 1 mg · wk 10 · n 211 · Phase 3 · secondary NCT01360632
  • -3.3 vs -2.2 1 mg · wk 9 · n 225 · Phase 3 · secondary NCT01360632
  • -3.1 vs -2.2 1 mg · wk 9 · n 211 · Phase 3 · secondary NCT01360632
  • -7.7 vs -6.0 3 mg · wk 13 · n 226 · Phase 3 · secondary NCT01360632
  • -8.1 vs -5.9 3 mg · wk 13 · n 213 · Phase 3 · secondary NCT01360632
  • -6.8 vs -5.5 3 mg · wk 12 · n 226 · Phase 3 · secondary NCT01360632
  • -7.1 vs -5.5 3 mg · wk 12 · n 213 · Phase 3 · secondary NCT01360632
  • -5.6 vs -4.8 3 mg · wk 11 · n 226 · Phase 3 · secondary NCT01360632
  • -5.8 vs -4.9 3 mg · wk 11 · n 213 · Phase 3 · secondary NCT01360632
  • -4.8 vs -3.9 3 mg · wk 10 · n 226 · Phase 3 · secondary NCT01360632
  • -4.9 vs -4.0 3 mg · wk 10 · n 213 · Phase 3 · secondary NCT01360632
  • -2.5 vs -2.2 3 mg · wk 9 · n 226 · Phase 3 · secondary NCT01360632
  • -2.6 vs -2.2 3 mg · wk 9 · n 213 · Phase 3 · secondary NCT01360632
  • -11.1 vs -8.9 wk 14 · n 161 · Phase 3 · secondary NCT02196506
  • -6.3 vs -5.9 wk 6 · n 422 · Phase 3 · secondary NCT01838681
  • -11.8 vs -8.9 wk 14 · n 124 · Phase 3 · secondary NCT02196506
  • -4.4 vs -3.2 wk 4 · n 191 · Phase 3 · secondary NCT01727726
  • -2.6 vs -1.0 wk 2 · n 191 · Phase 3 · secondary NCT01727726
  • -8.2 vs -6.1 1.5 ± 0.5 mg high dose · wk 14 · n 118 · Phase 2 · primary NCT00797966
  • -6.5 vs -6.1 0.5 ± 0.25 mg low dose · wk 14 · n 119 · Phase 2 · primary NCT00797966
  • -6.6 vs -6.1 0.15 mg fixed dose · wk 14 · n 62 · Phase 2 · primary NCT00797966
  • -8.2 vs -7.0 wk 14 · n 184 · Phase 2 · primary NCT01052077
  • -7.2 vs -5.5 1.5 ± 0.5 mg high dose · wk 13 · n 118 · Phase 2 · secondary NCT00797966
  • -7.0 vs -4.4 1.5 ± 0.5 mg high dose · wk 12 · n 118 · Phase 2 · secondary NCT00797966
  • -5.9 vs -4.4 1.5 ± 0.5 mg high dose · wk 11 · n 118 · Phase 2 · secondary NCT00797966
  • -5.0 vs -3.6 1.5 ± 0.5 mg high dose · wk 10 · n 118 · Phase 2 · secondary NCT00797966
  • -2.8 vs -2.5 1.5 ± 0.5 mg high dose · wk 9 · n 118 · Phase 2 · secondary NCT00797966
  • -6.8 vs -5.5 0.5 ± 0.25 mg low dose · wk 13 · n 119 · Phase 2 · secondary NCT00797966
  • -6.3 vs -4.4 0.5 ± 0.25 mg low dose · wk 12 · n 119 · Phase 2 · secondary NCT00797966
  • -5.7 vs -4.4 0.5 ± 0.25 mg low dose · wk 11 · n 119 · Phase 2 · secondary NCT00797966
  • -3.8 vs -3.6 0.5 ± 0.25 mg low dose · wk 10 · n 119 · Phase 2 · secondary NCT00797966
  • -3 vs -2.5 0.5 ± 0.25 mg low dose · wk 9 · n 119 · Phase 2 · secondary NCT00797966
  • -6.9 vs -5.5 0.15 mg fixed dose · wk 13 · n 62 · Phase 2 · secondary NCT00797966
  • -7.0 vs -4.4 0.15 mg fixed dose · wk 12 · n 62 · Phase 2 · secondary NCT00797966
  • -5.5 vs -4.4 0.15 mg fixed dose · wk 11 · n 62 · Phase 2 · secondary NCT00797966
  • -3.7 vs -3.6 0.15 mg fixed dose · wk 10 · n 62 · Phase 2 · secondary NCT00797966
  • -2.1 vs -2.5 0.15 mg fixed dose · wk 9 · n 62 · Phase 2 · secondary NCT00797966
  • -8.2 vs -7.0 wk 14 · n 184 · Phase 2 · secondary NCT01052077
  • -9 vs -7.2 wk 13 · n 184 · Phase 2 · secondary NCT01052077
  • -8.4 vs -6.2 wk 12 · n 184 · Phase 2 · secondary NCT01052077
  • -7.2 vs -5.2 wk 11 · n 184 · Phase 2 · secondary NCT01052077
  • -5.9 vs -4.0 wk 10 · n 184 · Phase 2 · secondary NCT01052077
  • -3.3 vs -2.0 wk 9 · n 184 · Phase 2 · secondary NCT01052077

CGI-S, change (acute)

Aripiprazole (Abilify)
—Not posted · NCT00095823
Brexpiprazole (Rexulti)
-0.9 vs -0.6−0.3 vs placebo2 mg/Day · wk 14 · n 187NCT01360645
60 other results
  • -0.9 vs -0.6 2 mg/Day · wk 14 · n 175 · Phase 3 · secondary NCT01360645
  • -0.9 vs -0.5 2 mg/Day · wk 13 · n 187 · Phase 3 · secondary NCT01360645
  • -0.8 vs -0.5 2 mg/Day · wk 13 · n 175 · Phase 3 · secondary NCT01360645
  • -0.7 vs -0.5 2 mg/Day · wk 12 · n 187 · Phase 3 · secondary NCT01360645
  • -0.7 vs -0.5 2 mg/Day · wk 12 · n 175 · Phase 3 · secondary NCT01360645
  • -0.6 vs -0.4 2 mg/Day · wk 11 · n 187 · Phase 3 · secondary NCT01360645
  • -0.6 vs -0.4 2 mg/Day · wk 11 · n 175 · Phase 3 · secondary NCT01360645
  • -0.5 vs -0.3 2 mg/Day · wk 10 · n 187 · Phase 3 · secondary NCT01360645
  • -0.4 vs -0.3 2 mg/Day · wk 10 · n 175 · Phase 3 · secondary NCT01360645
  • -0.3 vs -0.1 2 mg/Day · wk 9 · n 187 · Phase 3 · secondary NCT01360645
  • -0.2 vs -0.1 2 mg/Day · wk 9 · n 175 · Phase 3 · secondary NCT01360645
  • -0.9 vs -0.8 1 mg · wk 14 · n 225 · Phase 3 · secondary NCT01360632
  • -0.9 vs -0.7 1 mg · wk 14 · n 211 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.7 1 mg · wk 13 · n 225 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.6 1 mg · wk 13 · n 211 · Phase 3 · secondary NCT01360632
  • -0.7 vs -0.6 1 mg · wk 12 · n 225 · Phase 3 · secondary NCT01360632
  • -0.7 vs -0.6 1 mg · wk 12 · n 211 · Phase 3 · secondary NCT01360632
  • -0.6 vs -0.4 1 mg · wk 11 · n 225 · Phase 3 · secondary NCT01360632
  • -0.6 vs -0.5 1 mg · wk 11 · n 211 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.3 1 mg · wk 10 · n 225 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.3 1 mg · wk 10 · n 211 · Phase 3 · secondary NCT01360632
  • -0.3 vs -0.2 1 mg · wk 9 · n 225 · Phase 3 · secondary NCT01360632
  • -0.2 vs -0.2 1 mg · wk 9 · n 211 · Phase 3 · secondary NCT01360632
  • -0.9 vs -0.8 3 mg · wk 14 · n 226 · Phase 3 · secondary NCT01360632
  • -0.9 vs -0.7 3 mg · wk 14 · n 213 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.7 3 mg · wk 13 · n 226 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.6 3 mg · wk 13 · n 213 · Phase 3 · secondary NCT01360632
  • -0.7 vs -0.6 3 mg · wk 12 · n 226 · Phase 3 · secondary NCT01360632
  • -0.7 vs -0.6 3 mg · wk 12 · n 213 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.4 3 mg · wk 11 · n 226 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.5 3 mg · wk 11 · n 213 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.3 3 mg · wk 10 · n 226 · Phase 3 · secondary NCT01360632
  • -0.5 vs -0.3 3 mg · wk 10 · n 213 · Phase 3 · secondary NCT01360632
  • -0.2 vs -0.2 3 mg · wk 9 · n 226 · Phase 3 · secondary NCT01360632
  • -0.2 vs -0.2 3 mg · wk 9 · n 213 · Phase 3 · secondary NCT01360632
  • -0.8 vs -0.8 wk 6 · n 422 · Phase 3 · secondary NCT01838681
  • -1.1 vs -0.7 1.5 ± 0.5 mg high dose · wk 14 · n 118 · Phase 2 · secondary NCT00797966
  • -0.9 vs -0.6 1.5 ± 0.5 mg high dose · wk 13 · n 118 · Phase 2 · secondary NCT00797966
  • -0.9 vs -0.5 1.5 ± 0.5 mg high dose · wk 12 · n 118 · Phase 2 · secondary NCT00797966
  • -0.7 vs -0.5 1.5 ± 0.5 mg high dose · wk 11 · n 118 · Phase 2 · secondary NCT00797966
  • -0.6 vs -0.4 1.5 ± 0.5 mg high dose · wk 10 · n 118 · Phase 2 · secondary NCT00797966
  • -0.3 vs -0.2 1.5 ± 0.5 mg high dose · wk 9 · n 118 · Phase 2 · secondary NCT00797966
  • -0.8 vs -0.7 0.5 ± 0.25 mg low dose · wk 14 · n 119 · Phase 2 · secondary NCT00797966
  • -0.8 vs -0.6 0.5 ± 0.25 mg low dose · wk 13 · n 119 · Phase 2 · secondary NCT00797966
  • -0.7 vs -0.5 0.5 ± 0.25 mg low dose · wk 12 · n 119 · Phase 2 · secondary NCT00797966
  • -0.5 vs -0.5 0.5 ± 0.25 mg low dose · wk 11 · n 119 · Phase 2 · secondary NCT00797966
  • -0.4 vs -0.4 0.5 ± 0.25 mg low dose · wk 10 · n 119 · Phase 2 · secondary NCT00797966
  • -0.3 vs -0.2 0.5 ± 0.25 mg low dose · wk 9 · n 119 · Phase 2 · secondary NCT00797966
  • -0.8 vs -0.7 0.15 mg fixed dose · wk 14 · n 62 · Phase 2 · secondary NCT00797966
  • -0.7 vs -0.6 0.15 mg fixed dose · wk 13 · n 62 · Phase 2 · secondary NCT00797966
  • -0.8 vs -0.5 0.15 mg fixed dose · wk 12 · n 62 · Phase 2 · secondary NCT00797966
  • -0.5 vs -0.5 0.15 mg fixed dose · wk 11 · n 62 · Phase 2 · secondary NCT00797966
  • -0.4 vs -0.4 0.15 mg fixed dose · wk 10 · n 62 · Phase 2 · secondary NCT00797966
  • -0.2 vs -0.2 0.15 mg fixed dose · wk 9 · n 62 · Phase 2 · secondary NCT00797966
  • -0.9 vs -0.8 wk 14 · n 184 · Phase 2 · secondary NCT01052077
  • -1 vs -0.8 wk 13 · n 184 · Phase 2 · secondary NCT01052077
  • -0.9 vs -0.7 wk 12 · n 184 · Phase 2 · secondary NCT01052077
  • -0.8 vs -0.6 wk 11 · n 184 · Phase 2 · secondary NCT01052077
  • -0.6 vs -0.4 wk 10 · n 184 · Phase 2 · secondary NCT01052077
  • -0.3 vs -0.2 wk 9 · n 184 · Phase 2 · secondary NCT01052077

MADRS response

Aripiprazole (Abilify)
—Not posted · NCT00095823
Brexpiprazole (Rexulti)
23.5% vs 14.7%+8.8 vs placebo2 mg/Day · wk 14 · n 187NCT01360645
51 other results
  • 23.4% vs 15.7% 2 mg/Day · wk 14 · n 175 · Phase 3 · secondary NCT01360645
  • 23.1% vs 15.1% 1 mg · wk 14 · n 225 · Phase 3 · secondary NCT01360632
  • 23.2% vs 14.3% 1 mg · wk 14 · n 211 · Phase 3 · secondary NCT01360632
  • 18.2% vs 15.6% 1 mg · wk 13 · n 225 · Phase 3 · secondary NCT01360632
  • 18% vs 14.3% 1 mg · wk 13 · n 211 · Phase 3 · secondary NCT01360632
  • 16.9% vs 10.1% 1 mg · wk 12 · n 225 · Phase 3 · secondary NCT01360632
  • 16.6% vs 10.3% 1 mg · wk 12 · n 211 · Phase 3 · secondary NCT01360632
  • 13.3% vs 8.7% 1 mg · wk 11 · n 225 · Phase 3 · secondary NCT01360632
  • 13.3% vs 8.4% 1 mg · wk 11 · n 211 · Phase 3 · secondary NCT01360632
  • 10.2% vs 5.0% 1 mg · wk 10 · n 225 · Phase 3 · secondary NCT01360632
  • 7.6% vs 4.9% 1 mg · wk 10 · n 211 · Phase 3 · secondary NCT01360632
  • 4.5% vs 2.8% 1 mg · wk 9 · n 225 · Phase 3 · secondary NCT01360632
  • 3.4% vs 3.0% 1 mg · wk 9 · n 211 · Phase 3 · secondary NCT01360632
  • 22.1% vs 15.1% 3 mg · wk 14 · n 226 · Phase 3 · secondary NCT01360632
  • 23% vs 14.3% 3 mg · wk 14 · n 213 · Phase 3 · secondary NCT01360632
  • 18.6% vs 15.6% 3 mg · wk 13 · n 226 · Phase 3 · secondary NCT01360632
  • 19.2% vs 14.3% 3 mg · wk 13 · n 213 · Phase 3 · secondary NCT01360632
  • 15.5% vs 10.1% 3 mg · wk 12 · n 226 · Phase 3 · secondary NCT01360632
  • 16.4% vs 10.3% 3 mg · wk 12 · n 213 · Phase 3 · secondary NCT01360632
  • 10.6% vs 8.7% 3 mg · wk 11 · n 226 · Phase 3 · secondary NCT01360632
  • 11.3% vs 8.4% 3 mg · wk 11 · n 213 · Phase 3 · secondary NCT01360632
  • 6.2% vs 5.0% 3 mg · wk 10 · n 226 · Phase 3 · secondary NCT01360632
  • 6.1% vs 4.9% 3 mg · wk 10 · n 213 · Phase 3 · secondary NCT01360632
  • 0.5% vs 2.8% 3 mg · wk 9 · n 226 · Phase 3 · secondary NCT01360632
  • 0.5% vs 3.0% 3 mg · wk 9 · n 213 · Phase 3 · secondary NCT01360632
  • 10.5% vs 6.8% wk 6 · n 191 · Phase 3 · secondary NCT01727726
  • 18.6% vs 17.3% wk 6 · n 442 · Phase 3 · secondary NCT01838681
  • 34.7% vs 19.8% 1.5 ± 0.5 mg high dose · wk 14 · n 118 · Phase 2 · secondary NCT00797966
  • 25.4% vs 18.3% 1.5 ± 0.5 mg high dose · wk 13 · n 118 · Phase 2 · secondary NCT00797966
  • 25.4% vs 11.9% 1.5 ± 0.5 mg high dose · wk 12 · n 118 · Phase 2 · secondary NCT00797966
  • 18.6% vs 13.5% 1.5 ± 0.5 mg high dose · wk 11 · n 118 · Phase 2 · secondary NCT00797966
  • 11% vs 9.5% 1.5 ± 0.5 mg high dose · wk 10 · n 118 · Phase 2 · secondary NCT00797966
  • 2.6% vs 8.3% 1.5 ± 0.5 mg high dose · wk 9 · n 118 · Phase 2 · secondary NCT00797966
  • 20.2% vs 19.8% 0.5 ± 0.25 mg low dose · wk 14 · n 119 · Phase 2 · secondary NCT00797966
  • 22.7% vs 18.3% 0.5 ± 0.25 mg low dose · wk 13 · n 119 · Phase 2 · secondary NCT00797966
  • 15.1% vs 11.9% 0.5 ± 0.25 mg low dose · wk 12 · n 119 · Phase 2 · secondary NCT00797966
  • 15.1% vs 13.5% 0.5 ± 0.25 mg low dose · wk 11 · n 119 · Phase 2 · secondary NCT00797966
  • 8.4% vs 9.5% 0.5 ± 0.25 mg low dose · wk 10 · n 119 · Phase 2 · secondary NCT00797966
  • 6.8% vs 8.3% 0.5 ± 0.25 mg low dose · wk 9 · n 119 · Phase 2 · secondary NCT00797966
  • 27.4% vs 19.8% 0.15 mg fixed dose · wk 14 · n 62 · Phase 2 · secondary NCT00797966
  • 24.2% vs 18.3% 0.15 mg fixed dose · wk 13 · n 62 · Phase 2 · secondary NCT00797966
  • 30.6% vs 11.9% 0.15 mg fixed dose · wk 12 · n 62 · Phase 2 · secondary NCT00797966
  • 19.4% vs 13.5% 0.15 mg fixed dose · wk 11 · n 62 · Phase 2 · secondary NCT00797966
  • 8.1% vs 9.5% 0.15 mg fixed dose · wk 10 · n 62 · Phase 2 · secondary NCT00797966
  • 4.9% vs 8.3% 0.15 mg fixed dose · wk 9 · n 62 · Phase 2 · secondary NCT00797966
  • 29.9% vs 19.9% wk 14 · n 184 · Phase 2 · secondary NCT01052077
  • 29.9% vs 18.2% wk 13 · n 184 · Phase 2 · secondary NCT01052077
  • 30.4% vs 15.5% wk 12 · n 184 · Phase 2 · secondary NCT01052077
  • 22.3% vs 14.4% wk 11 · n 184 · Phase 2 · secondary NCT01052077
  • 15.8% vs 8.8% wk 10 · n 184 · Phase 2 · secondary NCT01052077
  • 6% vs 2.2% wk 9 · n 184 · Phase 2 · secondary NCT01052077

MADRS remission

Aripiprazole (Abilify)
—Not posted · NCT00095823
Brexpiprazole (Rexulti)
14.4% vs 8.4%+6 vs placebo2 mg/Day · wk 14 · n 187NCT01360645
50 other results
  • 14.9% vs 9.0% 2 mg/Day · wk 14 · n 175 · Phase 3 · secondary NCT01360645
  • 15.1% vs 11.9% 1 mg · wk 14 · n 222 · Phase 3 · secondary NCT01360632
  • 14.7% vs 10.8% 1 mg · wk 14 · n 211 · Phase 3 · secondary NCT01360632
  • 10.7% vs 9.2% 1 mg · wk 13 · n 222 · Phase 3 · secondary NCT01360632
  • 9.9% vs 8.4% 1 mg · wk 13 · n 211 · Phase 3 · secondary NCT01360632
  • 11.1% vs 6.0% 1 mg · wk 12 · n 222 · Phase 3 · secondary NCT01360632
  • 10.4% vs 6.4% 1 mg · wk 12 · n 211 · Phase 3 · secondary NCT01360632
  • 8.4% vs 5.5% 1 mg · wk 11 · n 222 · Phase 3 · secondary NCT01360632
  • 8.1% vs 5.4% 1 mg · wk 11 · n 211 · Phase 3 · secondary NCT01360632
  • 4% vs 4.1% 1 mg · wk 10 · n 222 · Phase 3 · secondary NCT01360632
  • 2.4% vs 3.9% 1 mg · wk 10 · n 211 · Phase 3 · secondary NCT01360632
  • 3.1% vs 2.8% 1 mg · wk 9 · n 222 · Phase 3 · secondary NCT01360632
  • 1.9% vs 3.0% 1 mg · wk 9 · n 211 · Phase 3 · secondary NCT01360632
  • 13.7% vs 11.9% 3 mg · wk 14 · n 221 · Phase 3 · secondary NCT01360632
  • 14.1% vs 10.8% 3 mg · wk 14 · n 213 · Phase 3 · secondary NCT01360632
  • 12.8% vs 9.2% 3 mg · wk 13 · n 221 · Phase 3 · secondary NCT01360632
  • 13.1% vs 8.4% 3 mg · wk 13 · n 213 · Phase 3 · secondary NCT01360632
  • 8.8% vs 6.0% 3 mg · wk 12 · n 221 · Phase 3 · secondary NCT01360632
  • 9.4% vs 6.4% 3 mg · wk 12 · n 213 · Phase 3 · secondary NCT01360632
  • 6.2% vs 5.5% 3 mg · wk 11 · n 221 · Phase 3 · secondary NCT01360632
  • 6.6% vs 5.4% 3 mg · wk 11 · n 213 · Phase 3 · secondary NCT01360632
  • 2.6% vs 4.1% 3 mg · wk 10 · n 221 · Phase 3 · secondary NCT01360632
  • 2.8% vs 3.9% 3 mg · wk 10 · n 213 · Phase 3 · secondary NCT01360632
  • 0.5% vs 2.8% 3 mg · wk 9 · n 221 · Phase 3 · secondary NCT01360632
  • 0.5% vs 3.0% 3 mg · wk 9 · n 213 · Phase 3 · secondary NCT01360632
  • 12% vs 10.5% wk 6 · n 442 · Phase 3 · secondary NCT01838681
  • 23.7% vs 13.5% 1.5 ± 0.5 mg high dose · wk 14 · n 118 · Phase 2 · secondary NCT00797966
  • 15.3% vs 15.1% 1.5 ± 0.5 mg high dose · wk 13 · n 118 · Phase 2 · secondary NCT00797966
  • 19.5% vs 10.3% 1.5 ± 0.5 mg high dose · wk 12 · n 118 · Phase 2 · secondary NCT00797966
  • 14.4% vs 11.1% 1.5 ± 0.5 mg high dose · wk 11 · n 118 · Phase 2 · secondary NCT00797966
  • 10.2% vs 8.7% 1.5 ± 0.5 mg high dose · wk 10 · n 118 · Phase 2 · secondary NCT00797966
  • 1.7% vs 4.1% 1.5 ± 0.5 mg high dose · wk 9 · n 118 · Phase 2 · secondary NCT00797966
  • 15.1% vs 13.5% 0.5 ± 0.25 mg low dose · wk 14 · n 119 · Phase 2 · secondary NCT00797966
  • 16.8% vs 15.1% 0.5 ± 0.25 mg low dose · wk 13 · n 119 · Phase 2 · secondary NCT00797966
  • 10.1% vs 10.3% 0.5 ± 0.25 mg low dose · wk 12 · n 119 · Phase 2 · secondary NCT00797966
  • 10.1% vs 11.1% 0.5 ± 0.25 mg low dose · wk 11 · n 119 · Phase 2 · secondary NCT00797966
  • 5.0% vs 8.7% 0.5 ± 0.25 mg low dose · wk 10 · n 119 · Phase 2 · secondary NCT00797966
  • 1.7% vs 4.1% 0.5 ± 0.25 mg low dose · wk 9 · n 119 · Phase 2 · secondary NCT00797966
  • 22.6% vs 13.5% 0.15 mg fixed dose · wk 14 · n 62 · Phase 2 · secondary NCT00797966
  • 19.4% vs 15.1% 0.15 mg fixed dose · wk 13 · n 62 · Phase 2 · secondary NCT00797966
  • 21% vs 10.3% 0.15 mg fixed dose · wk 12 · n 62 · Phase 2 · secondary NCT00797966
  • 12.9% vs 11.1% 0.15 mg fixed dose · wk 11 · n 62 · Phase 2 · secondary NCT00797966
  • 8.1% vs 8.7% 0.15 mg fixed dose · wk 10 · n 62 · Phase 2 · secondary NCT00797966
  • 3.3% vs 4.1% 0.15 mg fixed dose · wk 9 · n 62 · Phase 2 · secondary NCT00797966
  • 26.1% vs 14.9% wk 14 · n 184 · Phase 2 · secondary NCT01052077
  • 25% vs 13.8% wk 13 · n 184 · Phase 2 · secondary NCT01052077
  • 22.8% vs 10.5% wk 12 · n 184 · Phase 2 · secondary NCT01052077
  • 16.8% vs 9.9% wk 11 · n 184 · Phase 2 · secondary NCT01052077
  • 8.2% vs 3.9% wk 10 · n 184 · Phase 2 · secondary NCT01052077
  • 3.8% vs 1.7% wk 9 · n 184 · Phase 2 · secondary NCT01052077

Relapse (% of patients)

Aripiprazole (Abilify)
—Not posted · NCT00095823
Brexpiprazole (Rexulti)
22.5% vs 20.6%+1.9 vs placebowk 26 · n 240NCT03538691
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Aripiprazole (Abilify): registry results are on file for Major Depressive Disorder, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Aripiprazole (Abilify): 0 of 4 rows · Brexpiprazole (Rexulti): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBrexpiprazole (Rexulti)
Dropout rate
—1 mga
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 32 more results
—1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
—3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
—3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
—2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
9%
NCT04830215 · Phase 4 · registry result, not featured evidence
—Brexpiprazole
NCT03149991 · Phase 4 · registry result, not featured evidence
16%Ketamine/Brexpiprazole Arm
NCT03149991 · Phase 4 · registry result, not featured evidence · combination
33.3%Phase A: Brexpiprazole + ADT
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
—Phase B: Brexpiprazole + ADT
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
—Phase C: Brexpiprazole + ADT
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
80.6%New Subjects
NCT03737474 · Phase 3 · registry result, not featured evidence
38.9%Rollover Subjects
NCT03737474 · Phase 3 · registry result, not featured evidence
40.6%
NCT01360866 · Phase 3 · registry result, not featured evidence
13.2%
NCT01727726 · Phase 3 · registry result, not featured evidence · combination
—Brexpiprazole and ADT
NCT01838681 · Phase 3 · registry result, not featured evidence
—Period B Brexpiprazole and ADT (24
NCT01838681 · Phase 3 · registry result, not featured evidence
33.3%Adjunct Brexpiprazole
NCT02400346 · Phase 3 · registry result, not featured evidence · combination
—Brex + ADT
NCT02400346 · Phase 3 · registry result, not featured evidence · combination
—
NCT02196506 · Phase 3 · registry result, not featured evidence · combination
38.3%
NCT02013609 · Phase 3 · registry result, not featured evidence
6.8%
NCT01942733 · Phase 3 · registry result, not featured evidence
7.4%
NCT01942785 · Phase 3 · registry result, not featured evidence
13.5%
NCT02013531 · Phase 3 · registry result, not featured evidence
11%2 mg
NCT03697603 · Phase 2/3 · registry result, not featured evidence
4.8%1 mg
NCT03697603 · Phase 2/3 · registry result, not featured evidence
—
NCT01447576 · Phase 2 · registry result, not featured evidence · combination
—
NCT01052077 · Phase 2 · registry result, not featured evidence
—1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
—0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
—0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
0%Brexpiprazole-Cohort 1
NCT01670279 · Phase 1 · registry result, not featured evidence
28.6%Brexpiprazole-Cohort 2
NCT01670279 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—1 mga
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 32 more results
—1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
—3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
—3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
—2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
4.9%
NCT04830215 · Phase 4 · registry result, not featured evidence
—Brexpiprazole
NCT03149991 · Phase 4 · registry result, not featured evidence
—Ketamine/Brexpiprazole Arm
NCT03149991 · Phase 4 · registry result, not featured evidence · combination
7.1%Phase A: Brexpiprazole + ADT
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
—Phase B: Brexpiprazole + ADT
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
—Phase C: Brexpiprazole + ADT
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
58.1%New Subjects
NCT03737474 · Phase 3 · registry result, not featured evidence
22.2%Rollover Subjects
NCT03737474 · Phase 3 · registry result, not featured evidence
8.6%
NCT01360866 · Phase 3 · registry result, not featured evidence
—
NCT01727726 · Phase 3 · registry result, not featured evidence · combination
—Brexpiprazole and ADT
NCT01838681 · Phase 3 · registry result, not featured evidence
—Period B Brexpiprazole and ADT (24
NCT01838681 · Phase 3 · registry result, not featured evidence
18.2%Adjunct Brexpiprazole
NCT02400346 · Phase 3 · registry result, not featured evidence · combination
—Brex + ADT
NCT02400346 · Phase 3 · registry result, not featured evidence · combination
—
NCT02196506 · Phase 3 · registry result, not featured evidence · combination
6.4%
NCT02013609 · Phase 3 · registry result, not featured evidence
—
NCT01942733 · Phase 3 · registry result, not featured evidence
3.7%
NCT01942785 · Phase 3 · registry result, not featured evidence
—
NCT02013531 · Phase 3 · registry result, not featured evidence
7.3%2 mg
NCT03697603 · Phase 2/3 · registry result, not featured evidence
1.2%1 mg
NCT03697603 · Phase 2/3 · registry result, not featured evidence
—
NCT01447576 · Phase 2 · registry result, not featured evidence · combination
—
NCT01052077 · Phase 2 · registry result, not featured evidence
—1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
—0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
—0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
0%Brexpiprazole-Cohort 1
NCT01670279 · Phase 1 · registry result, not featured evidence
14.3%Brexpiprazole-Cohort 2
NCT01670279 · Phase 1 · registry result, not featured evidence
Serious AEs
0.4%1 mga
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 32 more results
—1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
0.4%3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
—3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
1.1%2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
0%
NCT04830215 · Phase 4 · registry result, not featured evidence
0%Brexpiprazole
NCT03149991 · Phase 4 · registry result, not featured evidence
—Ketamine/Brexpiprazole Arm
NCT03149991 · Phase 4 · registry result, not featured evidence · combination
0.9%Phase A: Brexpiprazole + ADT
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
1.6%Phase B: Brexpiprazole + ADT
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
0.4%Phase C: Brexpiprazole + ADT
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
3.2%New Subjects
NCT03737474 · Phase 3 · registry result, not featured evidence
3.7%Rollover Subjects
NCT03737474 · Phase 3 · registry result, not featured evidence
3.3%
NCT01360866 · Phase 3 · registry result, not featured evidence
0%
NCT01727726 · Phase 3 · registry result, not featured evidence · combination
2%Brexpiprazole and ADT
NCT01838681 · Phase 3 · registry result, not featured evidence
—Period B Brexpiprazole and ADT (24
NCT01838681 · Phase 3 · registry result, not featured evidence
—Adjunct Brexpiprazole
NCT02400346 · Phase 3 · registry result, not featured evidence · combination
4.5%Brex + ADT
NCT02400346 · Phase 3 · registry result, not featured evidence · combination
0.5%
NCT02196506 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02013609 · Phase 3 · registry result, not featured evidence
0%
NCT01942733 · Phase 3 · registry result, not featured evidence
0%
NCT01942785 · Phase 3 · registry result, not featured evidence
2.7%
NCT02013531 · Phase 3 · registry result, not featured evidence
1.2%2 mg
NCT03697603 · Phase 2/3 · registry result, not featured evidence
1.2%1 mg
NCT03697603 · Phase 2/3 · registry result, not featured evidence
4.2%
NCT01447576 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01052077 · Phase 2 · registry result, not featured evidence
1.7%1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
0%0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
0%0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
0%Brexpiprazole-Cohort 1
NCT01670279 · Phase 1 · registry result, not featured evidence
0%Brexpiprazole-Cohort 2
NCT01670279 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
1 mga
headache 9.3% (placebo 7.7%)
nasopharyngitis 6.6% (placebo 1.8%)
weight increased 6.6% (placebo 0.9%)
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 27 more results
3 mg
akathisia 13.5% (placebo 2.3%)
headache 6.1% (placebo 7.7%)
somnolence 5.7% (placebo 0.5%)
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2 mg/Day
weight increased 8% (placebo 3.1%)
akathisia 7.4% (placebo 1%)
upper resporatory tract infection 3.2% (placebo 6.3%)
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
fatigue 10.8%
headache 10.8%
insomnia 10%
NCT04830215 · Phase 4 · registry result, not featured evidence
alteration in taste 16% (placebo 7.7%)
dizziness 16% (placebo 26.9%)
restlessness/akathisia 12% (placebo 3.8%)
NCT03149991 · Phase 4 · registry result, not featured evidence
headache 9.9% (placebo 0%)
akathisia 9.6% (placebo 0%)
somnolence 7.9% (placebo 0%)
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
weight increased 15.9% (placebo 5.2%)
headache 5.4% (placebo 0%)
akathisia 0% (placebo 0%)
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
weight increased 10.4% (placebo 5.2%)
akathisia 0% (placebo 0%)
headache 0% (placebo 0%)
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
akathisia 38.7%
tremor 19.4%
nasopharyngitis 16.1%
NCT03737474 · Phase 3 · registry result, not featured evidence
weight increased 36.1%
nasopharyngitis 21.8%
akathisia 21.3%
NCT03737474 · Phase 3 · registry result, not featured evidence
weight increased 14.2% (placebo 22.9%)
somnolence 8.5% (placebo 7.8%)
headache 7.8% (placebo 8.1%)
NCT01360866 · Phase 3 · registry result, not featured evidence
akathisia 6.1% (placebo 1.9%)
headache 5.6% (placebo 4.9%)
somnolence 5.6% (placebo 1%)
NCT01727726 · Phase 3 · registry result, not featured evidence · combination
weight increased 9.5% (placebo 5%)
headache 7.7% (placebo 7%)
nasopharyngitis 6.3% (placebo 7.7%)
NCT01838681 · Phase 3 · registry result, not featured evidence
fatigue 15.2%
restlessness 12.9%
increased appetite 9.8%
NCT02400346 · Phase 3 · registry result, not featured evidence · combination
akathisia 8.3% (placebo 5%)
restlessness 8.3% (placebo 2%)
upper respiratory tract infection 5.2% (placebo 5%)
NCT02196506 · Phase 3 · registry result, not featured evidence · combination
headache 21.3%
somnolence 17%
weight increased 17%
NCT02013609 · Phase 3 · registry result, not featured evidence
nausea 13.6%
sedation 13.6%
headache 11.4%
NCT01942733 · Phase 3 · registry result, not featured evidence
akathisia 20.4%
headache 11.1%
dry mouth 7.4%
NCT01942785 · Phase 3 · registry result, not featured evidence
increased appetite 13.5%
diarrhoea 10.8%
dizziness 10.8%
NCT02013531 · Phase 3 · registry result, not featured evidence
2 mg
akathisia 24.4% (placebo 1.2%)
weight increased 7.7% (placebo 2.5%)
nasopharyngitis 6.5% (placebo 9.8%)
NCT03697603 · Phase 2/3 · registry result, not featured evidence
1 mg
nasopharyngitis 8% (placebo 9.8%)
weight increased 7.2% (placebo 2.5%)
tremor 6.4% (placebo 3.7%)
NCT03697603 · Phase 2/3 · registry result, not featured evidence
weight increased 21%
akathisia 9.9%
fatigue 9.2%
NCT01447576 · Phase 2 · registry result, not featured evidence · combination
akathisia 11.9% (placebo 4.8%)
weight increased 11.4% (placebo 2.7%)
insomnia 9.2% (placebo 3.2%)
NCT01052077 · Phase 2 · registry result, not featured evidence
1.5 ± 0.5 mg high dose
akathisia 8.3% (placebo 3.2%)
diarrhoea 8.3% (placebo 4%)
weight increased 7.4% (placebo 0.8%)
NCT00797966 · Phase 2 · registry result, not featured evidence
0.5 ± 0.25 mg low dose
upper respiratory tract infection 8.3% (placebo 4.8%)
headache 7.5% (placebo 9.5%)
nasopharyngitis 5.8% (placebo 1.6%)
NCT00797966 · Phase 2 · registry result, not featured evidence
0.15 mg fixed dose
headache 8.1% (placebo 9.5%)
insomnia 8.1% (placebo 3.2%)
akathisia 6.5% (placebo 3.2%)
NCT00797966 · Phase 2 · registry result, not featured evidence
pollakiuria 33.3% (placebo 0%)
weight increased 33.3% (placebo 0%)
atrioventricular block first degree 16.7% (placebo 0%)
NCT01670279 · Phase 1 · registry result, not featured evidence
dizziness 50% (placebo 0%)
dyspepsia 33.3% (placebo 0%)
nausea 33.3% (placebo 0%)
NCT01670279 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 28 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Brexpiprazole (Rexulti)

MADRS -8.27 vs -5.15 placebo score @ 14wk2 mg/Day
absolute change · score
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 71 more results
-8.36 vs -5.15 placebo score @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-3.15 vs -1.86 placebo score @ 9wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.15 vs -3.43 placebo score @ 10wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.69 vs -4.06 placebo score @ 11wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.22 vs -4.63 placebo score @ 12wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-8.28 vs -5.1 placebo score @ 13wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-3.05 vs -1.74 placebo score @ 9wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.04 vs -3.52 placebo score @ 10wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.58 vs -4.17 placebo score @ 11wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.24 vs -4.72 placebo score @ 12wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-8.28 vs -5.01 placebo score @ 13wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-8.2 vs -6.7 placebo score @ 6wk2 mg
NCT03697603 · Phase 2/3 · registry result, not featured evidence
-7.65 vs -6.45 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.64 vs 6.33 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-3.25 vs -2.19 placebo score @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.34 vs -3.91 placebo score @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.25 vs -4.85 placebo score @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.08 vs -5.52 placebo score @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.55 vs -6.04 placebo score @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-3.09 vs -2.18 placebo score @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.12 vs -3.95 placebo score @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.22 vs -4.86 placebo score @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.09 vs -5.48 placebo score @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.56 vs -5.93 placebo score @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-8.5 vs -6.7 placebo score @ 6wk1 mg
NCT03697603 · Phase 2/3 · registry result, not featured evidence
-8.23 vs -6.09 placebo score @ 14wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-2.75 vs -2.48 placebo score @ 9wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-4.97 vs -3.64 placebo score @ 10wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.88 vs -4.4 placebo score @ 11wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-7.01 vs -4.41 placebo score @ 12wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-7.18 vs -5.47 placebo score @ 13wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-7.98 vs -6.45 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-8.29 vs 6.33 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-2.53 vs -2.19 placebo score @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-4.8 vs -3.91 placebo score @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.56 vs -4.85 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.8 vs -5.52 placebo score @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.73 vs -6.04 placebo score @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-2.6 vs -2.18 placebo score @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-4.92 vs -3.95 placebo score @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.76 vs -4.86 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.11 vs -5.48 placebo score @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-8.05 vs -5.93 placebo score @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.46 vs -6.09 placebo score @ 14wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-3 vs -2.48 placebo score @ 9wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-3.78 vs -3.64 placebo score @ 10wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.71 vs -4.4 placebo score @ 11wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-6.31 vs -4.41 placebo score @ 12wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-6.76 vs -5.47 placebo score @ 13wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-6.62 vs -6.09 placebo score @ 14wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-2.13 vs -2.48 placebo score @ 9wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-3.69 vs -3.64 placebo score @ 10wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.53 vs -4.4 placebo score @ 11wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-6.97 vs -4.41 placebo score @ 12wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-6.9 vs -5.47 placebo score @ 13wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
4.09 vs 4.21 placebo score @ 46wk
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
-6.04 vs -4.57 placebo score
NCT01727726 · Phase 3 · registry result, not featured evidence · combination
-2.57 vs -1.04 placebo score @ 2wk
NCT01727726 · Phase 3 · registry result, not featured evidence · combination
-4.39 vs -3.22 placebo score @ 4wk
NCT01727726 · Phase 3 · registry result, not featured evidence · combination
-6.3 vs -5.9 placebo score @ 6wk
NCT01838681 · Phase 3 · registry result, not featured evidence
-11.5 vs -12.6 placebo score @ 24wk
NCT01838681 · Phase 3 · registry result, not featured evidence
-10.4 vs -8.07 placebo score @ 14wk
NCT02196506 · Phase 3 · registry result, not featured evidence · combination
-11.1 vs -8.87 placebo score @ 14wk
NCT02196506 · Phase 3 · registry result, not featured evidence · combination
-11.8 vs -8.87 placebo score @ 14wk
NCT02196506 · Phase 3 · registry result, not featured evidence · combination
-8.2 vs -7.02 placebo score @ 14wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-3.3 vs -1.99 placebo score @ 9wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-5.92 vs -4.01 placebo score @ 10wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-7.23 vs -5.22 placebo score @ 11wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-8.42 vs -6.21 placebo score @ 12wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-9 vs -7.18 placebo score @ 13wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-8.2 vs -7.02 placebo score @ 14wk
NCT01052077 · Phase 2 · registry result, not featured evidence
SDS Mean -1.13 vs -0.58 placebo score @ 11wk1 mg
absolute change · score
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 11 more results
-1.33 vs -0.84 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-1.11 vs -0.53 placebo score @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-1.27 vs -0.78 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-1.27 vs -0.61 placebo score @ 14wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.67 vs -0.58 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-1.21 vs -0.84 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.74 vs -0.53 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-1.26 vs -0.78 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.8 vs -0.61 placebo score @ 14wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.84 vs -0.61 placebo score @ 14wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.7 vs -0.8 placebo score @ 52wk
NCT01360866 · Phase 3 · registry result, not featured evidence
CGI-S -0.25 vs -0.12 placebo score @ 9wk2 mg/Day
absolute change · score
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 63 more results
-0.45 vs -0.31 placebo score @ 10wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.61 vs -0.4 placebo score @ 11wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.7 vs -0.45 placebo score @ 12wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.86 vs -0.5 placebo score @ 13wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.91 vs -0.58 placebo score @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.24 vs -0.09 placebo score @ 9wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.43 vs -0.32 placebo score @ 10wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.58 vs -0.42 placebo score @ 11wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.7 vs -0.46 placebo score @ 12wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.85 vs -0.5 placebo score @ 13wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.91 vs -0.57 placebo score @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.25 vs -0.16 placebo score @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.52 vs -0.31 placebo score @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.64 vs -0.44 placebo score @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.73 vs -0.59 placebo score @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.78 vs -0.66 placebo score @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.86 vs -0.75 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.24 vs -0.16 placebo score @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.5 vs -0.33 placebo score @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.64 vs -0.45 placebo score @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.73 vs -0.58 placebo score @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.77 vs -0.64 placebo score @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.87 vs -0.72 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-1.06 vs -0.71 placebo score @ 14wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.33 vs -0.21 placebo score @ 9wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.61 vs -0.4 placebo score @ 10wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.69 vs -0.47 placebo score @ 11wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.86 vs -0.52 placebo score @ 12wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.88 vs -0.59 placebo score @ 13wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.22 vs -0.16 placebo score @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.46 vs -0.31 placebo score @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.51 vs -0.44 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.72 vs -0.59 placebo score @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.77 vs -0.66 placebo score @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.9 vs -0.75 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.23 vs -0.16 placebo score @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.47 vs -0.33 placebo score @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.53 vs -0.45 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.74 vs -0.58 placebo score @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.8 vs -0.64 placebo score @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.92 vs -0.72 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.81 vs -0.71 placebo score @ 14wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.26 vs -0.21 placebo score @ 9wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.39 vs -0.4 placebo score @ 10wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.53 vs -0.47 placebo score @ 11wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.66 vs -0.52 placebo score @ 12wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.78 vs -0.59 placebo score @ 13wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.83 vs -0.71 placebo score @ 14wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.21 vs -0.21 placebo score @ 9wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.42 vs -0.4 placebo score @ 10wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.53 vs -0.47 placebo score @ 11wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.76 vs -0.52 placebo score @ 12wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.74 vs -0.59 placebo score @ 13wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
0.56 vs 0.53 placebo score @ 46wk
NCT03538691 · Phase 3 · registry result, not featured evidence · combination
-0.63 vs -0.77 placebo score @ 52wk
NCT01360866 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.8 placebo score @ 6wk
NCT01838681 · Phase 3 · registry result, not featured evidence
-1.5 vs -1.7 placebo score @ 24wk
NCT01838681 · Phase 3 · registry result, not featured evidence
-0.29 vs -0.2 placebo score @ 9wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-0.58 vs -0.44 placebo score @ 10wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-0.76 vs -0.59 placebo score @ 11wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-0.94 vs -0.68 placebo score @ 12wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-1 vs -0.81 placebo score @ 13wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-0.95 vs -0.85 placebo score @ 14wk
NCT01052077 · Phase 2 · registry result, not featured evidence
IDS-SR -3.02 vs -1.45 placebo score @ 9wk2 mg/Day
absolute change · score
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 60 more results
-4.17 vs -2.64 placebo score @ 10wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.41 vs -4.31 placebo score @ 11wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.16 vs -4.69 placebo score @ 12wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7 vs -5.25 placebo score @ 13wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.49 vs -5.52 placebo score @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-3.3 vs -1.59 placebo score @ 9wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-4.29 vs -3.13 placebo score @ 10wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.45 vs -4.73 placebo score @ 11wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.32 vs -5.06 placebo score @ 12wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.03 vs -5.6 placebo score @ 13wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.59 vs -6.05 placebo score @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-3.58 vs -2.31 placebo score @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-4.97 vs -3.11 placebo score @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.83 vs -3.74 placebo score @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.33 vs -4.43 placebo score @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.96 vs -5.66 placebo score @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.02 vs -5.42 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-3.27 vs -2.15 placebo score @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-4.7 vs -2.94 placebo score @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.77 vs -3.46 placebo score @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.33 vs -4.18 placebo score @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.88 vs -5.25 placebo score @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.97 vs -5.07 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-2.04 vs -0.98 placebo score @ 9wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-4.08 vs -1.62 placebo score @ 10wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-4.82 vs -2.09 placebo score @ 11wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.77 vs -2.07 placebo score @ 12wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.65 vs -2.37 placebo score @ 13wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-6.74 vs -3.08 placebo score @ 14wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-2.68 vs -2.31 placebo score @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-4 vs -3.11 placebo score @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-4.15 vs -3.74 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.77 vs -4.43 placebo score @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.62 vs -5.66 placebo score @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.94 vs -5.42 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-2.65 vs -2.15 placebo score @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-4.13 vs -2.94 placebo score @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-4.29 vs -3.46 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.05 vs -4.18 placebo score @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.97 vs -5.25 placebo score @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-7.2 vs -5.07 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-1.88 vs -0.98 placebo score @ 9wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-2.58 vs -1.62 placebo score @ 10wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-3.41 vs -2.09 placebo score @ 11wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-3.77 vs -2.07 placebo score @ 12wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.22 vs -2.37 placebo score @ 13wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-4.96 vs -3.08 placebo score @ 14wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-0.98 vs -0.98 placebo score @ 9wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-2.13 vs -1.62 placebo score @ 10wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-3.58 vs -2.09 placebo score @ 11wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.11 vs -2.07 placebo score @ 12wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.34 vs -2.37 placebo score @ 13wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.55 vs -3.08 placebo score @ 14wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-4.76 vs -5.25 placebo score @ 52wk
NCT01360866 · Phase 3 · registry result, not featured evidence
-1.65 vs -1.99 placebo score @ 9wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-2.91 vs -2.93 placebo score @ 10wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-3.92 vs -3.64 placebo score @ 11wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-4.82 vs -4.76 placebo score @ 12wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-5.6 vs -5.59 placebo score @ 13wk
NCT01052077 · Phase 2 · registry result, not featured evidence
-5.7 vs -5.84 placebo score @ 14wk
NCT01052077 · Phase 2 · registry result, not featured evidence
HAM-D17 -5.47 vs -4.8 placebo score @ 14wk1 mg
absolute change · score
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 7 more results
-5.36 vs -4.57 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.59 vs -5.23 placebo score @ 14wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-6.14 vs -4.8 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-6.26 vs -4.57 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-5.28 vs -5.23 placebo score @ 14wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.77 vs -5.23 placebo score @ 14wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
-5.98 vs -5.4 placebo score @ 14wk
NCT01052077 · Phase 2 · registry result, not featured evidence
HAM-A -3.43 vs -3.33 placebo score @ 14wk1 mg
absolute change · score
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 3 more results
-3.35 vs -3.07 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-3.89 vs -3.33 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
-3.96 vs -3.07 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
CGI-I 3.41 vs 3.62 placebo score @ 9wk2 mg/Day
absolute value · score
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 59 more results
3.17 vs 3.37 placebo score @ 10wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.03 vs 3.23 placebo score @ 11wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.84 vs 3.19 placebo score @ 12wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.74 vs 3.13 placebo score @ 13wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.75 vs 3.13 placebo score @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.44 vs 3.67 placebo score @ 9wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.21 vs 3.4 placebo score @ 10wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.07 vs 3.25 placebo score @ 11wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.85 vs 3.23 placebo score @ 12wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.78 vs 3.18 placebo score @ 13wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.77 vs 3.17 placebo score @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.36 vs 3.51 placebo score @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.08 vs 3.34 placebo score @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.91 vs 3.17 placebo score @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.78 vs 3.02 placebo score @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.72 vs 2.97 placebo score @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.69 vs 2.85 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.39 vs 3.54 placebo score @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.1 vs 3.35 placebo score @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.93 vs 3.19 placebo score @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.8 vs 3.06 placebo score @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.75 vs 3.01 placebo score @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.71 vs 2.9 placebo score @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.2 vs 3.31 placebo score @ 9wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.95 vs 3.11 placebo score @ 10wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.8 vs 2.94 placebo score @ 11wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.7 vs 2.95 placebo score @ 12wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.64 vs 2.9 placebo score @ 13wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.52 vs 2.83 placebo score @ 14wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
3.4 vs 3.51 placebo score @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.09 vs 3.34 placebo score @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.99 vs 3.17 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.81 vs 3.02 placebo score @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.73 vs 2.97 placebo score @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.66 vs 2.85 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.42 vs 3.54 placebo score @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.08 vs 3.35 placebo score @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.99 vs 3.19 placebo score @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.81 vs 3.06 placebo score @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.72 vs 3.01 placebo score @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.65 vs 2.9 placebo score @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.3 vs 3.31 placebo score @ 9wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
3.19 vs 3.11 placebo score @ 10wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
3.02 vs 2.94 placebo score @ 11wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.9 vs 2.95 placebo score @ 12wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.76 vs 2.9 placebo score @ 13wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.78 vs 2.83 placebo score @ 14wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
3.39 vs 3.31 placebo score @ 9wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
3.16 vs 3.11 placebo score @ 10wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.94 vs 2.94 placebo score @ 11wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.87 vs 2.95 placebo score @ 12wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.85 vs 2.9 placebo score @ 13wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
2.74 vs 2.83 placebo score @ 14wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
3.33 vs 3.37 placebo score @ 9wk
NCT01052077 · Phase 2 · registry result, not featured evidence
3.03 vs 3.15 placebo score @ 10wk
NCT01052077 · Phase 2 · registry result, not featured evidence
3 vs 3.02 placebo score @ 11wk
NCT01052077 · Phase 2 · registry result, not featured evidence
2.63 vs 2.91 placebo score @ 12wk
NCT01052077 · Phase 2 · registry result, not featured evidence
2.6 vs 2.8 placebo score @ 13wk
NCT01052077 · Phase 2 · registry result, not featured evidence
2.68 vs 2.78 placebo score @ 14wk
NCT01052077 · Phase 2 · registry result, not featured evidence
MADRS 23.5% (n=187) vs 14.7% (n=191) placebo @ 14wk2 mg/Day
responder rate · % of participants
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 52 more results
23.4% (n=175) vs 15.7% (n=178) placebo @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
4.5% (n=225) vs 2.8% (n=218) placebo @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
10.2% (n=225) vs 5.05% (n=218) placebo @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
13.3% (n=225) vs 8.72% (n=218) placebo @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
16.9% (n=225) vs 10.1% (n=218) placebo @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
18.2% (n=225) vs 15.6% (n=218) placebo @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
23.1% (n=225) vs 15.1% (n=218) placebo @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.37% (n=211) vs 3.02% (n=203) placebo @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
7.58% (n=211) vs 4.93% (n=203) placebo @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
13.3% (n=211) vs 8.37% (n=203) placebo @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
16.6% (n=211) vs 10.3% (n=203) placebo @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
18% (n=211) vs 14.3% (n=203) placebo @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
23.2% (n=211) vs 14.3% (n=203) placebo @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.59% (n=118) vs 8.26% (n=126) placebo @ 9wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
11% (n=118) vs 9.52% (n=126) placebo @ 10wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
18.6% (n=118) vs 13.5% (n=126) placebo @ 11wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
25.4% (n=118) vs 11.9% (n=126) placebo @ 12wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
25.4% (n=118) vs 18.3% (n=126) placebo @ 13wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
34.7% (n=118) vs 19.8% (n=126) placebo @ 14wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
0.45% (n=226) vs 2.8% (n=218) placebo @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
6.19% (n=226) vs 5.05% (n=218) placebo @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
10.6% (n=226) vs 8.72% (n=218) placebo @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
15.5% (n=226) vs 10.1% (n=218) placebo @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
18.6% (n=226) vs 15.6% (n=218) placebo @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
22.1% (n=226) vs 15.1% (n=218) placebo @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
0.48% (n=213) vs 3.02% (n=203) placebo @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
6.1% (n=213) vs 4.93% (n=203) placebo @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
11.3% (n=213) vs 8.37% (n=203) placebo @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
16.4% (n=213) vs 10.3% (n=203) placebo @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
19.2% (n=213) vs 14.3% (n=203) placebo @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
23% (n=213) vs 14.3% (n=203) placebo @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
6.84% (n=119) vs 8.26% (n=126) placebo @ 9wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
8.4% (n=119) vs 9.52% (n=126) placebo @ 10wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
15.1% (n=119) vs 13.5% (n=126) placebo @ 11wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
15.1% (n=119) vs 11.9% (n=126) placebo @ 12wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
22.7% (n=119) vs 18.3% (n=126) placebo @ 13wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
20.2% (n=119) vs 19.8% (n=126) placebo @ 14wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
4.92% (n=62) vs 8.26% (n=126) placebo @ 9wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
8.06% (n=62) vs 9.52% (n=126) placebo @ 10wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
19.4% (n=62) vs 13.5% (n=126) placebo @ 11wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
30.6% (n=62) vs 11.9% (n=126) placebo @ 12wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
24.2% (n=62) vs 18.3% (n=126) placebo @ 13wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
27.4% (n=62) vs 19.8% (n=126) placebo @ 14wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
10.5% (n=191) vs 6.8% (n=205) placebo @ 6wk*
NCT01727726 · Phase 3 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
18.6% (n=442) vs 17.3% (n=440) placebo @ 6wk*
NCT01838681 · Phase 3 · registry result, not featured evidence · converted to % from 82 participants as posted
50.5% (n=442) vs 53.6% (n=440) placebo @ 24wk*
NCT01838681 · Phase 3 · registry result, not featured evidence · converted to % from 223 participants as posted
6% (n=184) vs 2.2% (n=181) placebo @ 9wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 11 participants as posted
15.8% (n=184) vs 8.8% (n=181) placebo @ 10wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 29 participants as posted
22.3% (n=184) vs 14.4% (n=181) placebo @ 11wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 41 participants as posted
30.4% (n=184) vs 15.5% (n=181) placebo @ 12wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 56 participants as posted
29.9% (n=184) vs 18.2% (n=181) placebo @ 13wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 55 participants as posted
29.9% (n=184) vs 19.9% (n=181) placebo @ 14wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 55 participants as posted
MADRS Remission 14.4% (n=187) vs 8.38% (n=191) placebo @ 14wk2 mg/Day
responder rate · % of participants
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 52 more results
14.9% (n=175) vs 8.99% (n=178) placebo @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
3.15% (n=222) vs 2.8% (n=214) placebo @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
4% (n=222) vs 4.13% (n=214) placebo @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
8.44% (n=222) vs 5.5% (n=214) placebo @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
11.1% (n=222) vs 5.96% (n=214) placebo @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
10.7% (n=222) vs 9.17% (n=214) placebo @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
15.1% (n=222) vs 11.9% (n=214) placebo @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
1.92% (n=211) vs 3.02% (n=203) placebo @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.37% (n=211) vs 3.94% (n=203) placebo @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
8.06% (n=211) vs 5.42% (n=203) placebo @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
10.4% (n=211) vs 6.4% (n=203) placebo @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
9.95% (n=211) vs 8.37% (n=203) placebo @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
14.7% (n=211) vs 10.8% (n=203) placebo @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
1.72% (n=118) vs 4.13% (n=126) placebo @ 9wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
10.2% (n=118) vs 8.73% (n=126) placebo @ 10wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
14.4% (n=118) vs 11.1% (n=126) placebo @ 11wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
19.5% (n=118) vs 10.3% (n=126) placebo @ 12wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
15.3% (n=118) vs 15.1% (n=126) placebo @ 13wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
23.7% (n=118) vs 13.5% (n=126) placebo @ 14wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
0.45% (n=221) vs 2.8% (n=214) placebo @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.65% (n=221) vs 4.13% (n=214) placebo @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
6.19% (n=221) vs 5.5% (n=214) placebo @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
8.85% (n=221) vs 5.96% (n=214) placebo @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
12.8% (n=221) vs 9.17% (n=214) placebo @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
13.7% (n=221) vs 11.9% (n=214) placebo @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
0.48% (n=213) vs 3.02% (n=203) placebo @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
2.82% (n=213) vs 3.94% (n=203) placebo @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
6.57% (n=213) vs 5.42% (n=203) placebo @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
9.39% (n=213) vs 6.4% (n=203) placebo @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
13.1% (n=213) vs 8.37% (n=203) placebo @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
14.1% (n=213) vs 10.8% (n=203) placebo @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
1.71% (n=119) vs 4.13% (n=126) placebo @ 9wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
5.04% (n=119) vs 8.73% (n=126) placebo @ 10wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
10.1% (n=119) vs 11.1% (n=126) placebo @ 11wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
10.1% (n=119) vs 10.3% (n=126) placebo @ 12wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
16.8% (n=119) vs 15.1% (n=126) placebo @ 13wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
15.1% (n=119) vs 13.5% (n=126) placebo @ 14wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
3.28% (n=62) vs 4.13% (n=126) placebo @ 9wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
8.06% (n=62) vs 8.73% (n=126) placebo @ 10wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
12.9% (n=62) vs 11.1% (n=126) placebo @ 11wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
21% (n=62) vs 10.3% (n=126) placebo @ 12wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
19.4% (n=62) vs 15.1% (n=126) placebo @ 13wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
22.6% (n=62) vs 13.5% (n=126) placebo @ 14wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
21.4% (n=444) vs 24.9% (n=441) placebo @ 24wk*
NCT01838681 · Phase 3 · registry result, not featured evidence · converted to % from 95 participants as posted
12% (n=442) vs 10.5% (n=440) placebo @ 6wk*
NCT01838681 · Phase 3 · registry result, not featured evidence · converted to % from 53 participants as posted
39.8% (n=442) vs 45% (n=440) placebo @ 24wk*
NCT01838681 · Phase 3 · registry result, not featured evidence · converted to % from 176 participants as posted
3.8% (n=184) vs 1.7% (n=181) placebo @ 9wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 7 participants as posted
8.2% (n=184) vs 3.9% (n=181) placebo @ 10wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 15 participants as posted
16.8% (n=184) vs 9.9% (n=181) placebo @ 11wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 31 participants as posted
22.8% (n=184) vs 10.5% (n=181) placebo @ 12wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 42 participants as posted
25% (n=184) vs 13.8% (n=181) placebo @ 13wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 46 participants as posted
26.1% (n=184) vs 14.9% (n=181) placebo @ 14wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 48 participants as posted
CGI-I 44.4% (n=187) vs 27.7% (n=191) placebo @ 14wk2 mg/Day
responder rate · % of participants
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 50 more results
43.4% (n=175) vs 26.4% (n=178) placebo @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
9.46% (n=225) vs 6.54% (n=218) placebo @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
23.6% (n=225) vs 13.3% (n=218) placebo @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
28.4% (n=225) vs 21.6% (n=218) placebo @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
35.1% (n=225) vs 29.4% (n=218) placebo @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
40% (n=225) vs 28.9% (n=218) placebo @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
41.8% (n=225) vs 36.7% (n=218) placebo @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
7.69% (n=211) vs 5.53% (n=203) placebo @ 9wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
21.8% (n=211) vs 12.3% (n=203) placebo @ 10wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
27.5% (n=211) vs 19.7% (n=203) placebo @ 11wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
34.1% (n=211) vs 27.6% (n=203) placebo @ 12wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
38.9% (n=211) vs 27.1% (n=203) placebo @ 13wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
41.2% (n=211) vs 34% (n=203) placebo @ 14wk1 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
14.7% (n=118) vs 14.9% (n=126) placebo @ 9wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
24.6% (n=118) vs 27% (n=126) placebo @ 10wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
35.6% (n=118) vs 29.4% (n=126) placebo @ 11wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
42.4% (n=118) vs 31.7% (n=126) placebo @ 12wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
49.2% (n=118) vs 33.3% (n=126) placebo @ 13wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
52.5% (n=118) vs 41.3% (n=126) placebo @ 14wk1.5 ± 0.5 mg high dose
NCT00797966 · Phase 2 · registry result, not featured evidence
10.4% (n=226) vs 6.54% (n=218) placebo @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
23% (n=226) vs 13.3% (n=218) placebo @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
30.1% (n=226) vs 21.6% (n=218) placebo @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
38.1% (n=226) vs 29.4% (n=218) placebo @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
43.4% (n=226) vs 28.9% (n=218) placebo @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
47.8% (n=226) vs 36.7% (n=218) placebo @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
9.52% (n=213) vs 5.53% (n=203) placebo @ 9wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
23% (n=213) vs 12.3% (n=203) placebo @ 10wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
30% (n=213) vs 19.7% (n=203) placebo @ 11wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
38% (n=213) vs 27.6% (n=203) placebo @ 12wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
44.1% (n=213) vs 27.1% (n=203) placebo @ 13wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
48.4% (n=213) vs 34% (n=203) placebo @ 14wk3 mg
NCT01360632 · Phase 3 · combination · Major Depressive Disorder · phase 3
11.1% (n=119) vs 14.9% (n=126) placebo @ 9wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
17.6% (n=119) vs 27% (n=126) placebo @ 10wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
29.4% (n=119) vs 29.4% (n=126) placebo @ 11wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
33.6% (n=119) vs 31.7% (n=126) placebo @ 12wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
37% (n=119) vs 33.3% (n=126) placebo @ 13wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
37% (n=119) vs 41.3% (n=126) placebo @ 14wk0.5 ± 0.25 mg low dose
NCT00797966 · Phase 2 · registry result, not featured evidence
16.1% (n=62) vs 14.9% (n=126) placebo @ 9wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
25.8% (n=62) vs 27% (n=126) placebo @ 10wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
32.3% (n=62) vs 29.4% (n=126) placebo @ 11wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
35.5% (n=62) vs 31.7% (n=126) placebo @ 12wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
37.1% (n=62) vs 33.3% (n=126) placebo @ 13wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
38.7% (n=62) vs 41.3% (n=126) placebo @ 14wk0.15 mg fixed dose
NCT00797966 · Phase 2 · registry result, not featured evidence
52.4% (n=191) vs 38.5% (n=205) placebo @ 6wk*
NCT01727726 · Phase 3 · registry result, not featured evidence · combination · converted to % from 100 Participants as posted
12.5% (n=184) vs 10.5% (n=181) placebo @ 9wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 23 participants as posted
25.5% (n=184) vs 21.5% (n=181) placebo @ 10wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 47 participants as posted
39.7% (n=184) vs 28.2% (n=181) placebo @ 11wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 73 participants as posted
47.8% (n=184) vs 34.8% (n=181) placebo @ 12wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 88 participants as posted
48.9% (n=184) vs 38.7% (n=181) placebo @ 13wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 90 participants as posted
45.7% (n=184) vs 39.8% (n=181) placebo @ 14wk*
NCT01052077 · Phase 2 · registry result, not featured evidence · converted to % from 84 participants as posted
SDS -1.35 vs -0.91 placebo score @ 14wk2 mg/Day
absolute change · score
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 6 more results
-1.35 vs -0.89 placebo score @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
-0.97 vs -0.74 placebo score
NCT01727726 · Phase 3 · registry result, not featured evidence · combination
-2.9 vs -3 placebo score @ 6wk
NCT01838681 · Phase 3 · registry result, not featured evidence
-5.5 vs -6.7 placebo score @ 24wk
NCT01838681 · Phase 3 · registry result, not featured evidence
-1.63 vs -1.41 placebo score @ 14wk
NCT02196506 · Phase 3 · registry result, not featured evidence · combination
-0.91 vs -0.69 placebo score @ 14wk
NCT01052077 · Phase 2 · registry result, not featured evidence
HAM-D -5.89 vs -3.55 placebo score @ 14wk2 mg/Day
absolute change · score
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3
show 1 more result
-5.89 vs -3.59 placebo score @ 14wk2 mg/Day
NCT01360645 · Phase 3 · combination · Major Depressive Disorder · phase 3

+ 45 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify)'s landscape · Brexpiprazole (Rexulti)'s landscape